Protocol  CONFIDENTIAL  
Labcorp Drug Development Study: 8493285  AMG 510 20220024  
18 May 2022  Page 1 of 69 
Internal Use Only Medical and Scientific Affairs  Protocol  
An Open -label Study to Evaluate the Impact of Omeprazole, 
A Proton  Pump  Inhibitor, on the Pharmacokinetics of Sotorasib 
Coadministered with an Acidic Beverage  in Healthy Volunteers  
Protocol Status:  Final  
Protocol Date:  18 May 2022  
Original Protocol  
Investigational Product:  Sotorasib (AMG 510)  
Amgen Protocol Reference Number:  20220024  
Labcorp Drug Development Study Number:  8493285  
Sponsor:  
Amgen Inc.  
One Amgen Cen ter Drive  
Thousand Oaks, California 91320  
USA  
This protocol was developed, reviewed, and approved in accordance with Labcorp’s 
standard operating procedures. This format and content of this protocol is aligned with 
Good Clinical Practice: Consolidated Guidance (ICH E6).  
Study ID: [REMOVED]
This NCT number has been applied to the document for
purposes of posting on Clinicaltrials.gov
Protocol  CONFIDENTIAL  
Labcorp Drug Development Study: 8493285  AMG 510 20220024  
18 May 2022  Page 2 of 69 
Internal Use Only Medical and Scientific Affairs  Confidentiality Notice  
This document contains confidential information of Amgen Inc.  
This document must not be disclosed to anyone other than the site study staffs and 
members of the Institutional Review Board/Independent Ethics Commit tee/Institutional 
Scientific Review Board or equivalent.  
The information in this document cannot be used for any purpose other than the 
evaluation or conduct of the clinical investigation without the prior written consent of 
Amgen Inc.  
If you have question s regarding how this document may be used or shared, call the 
Amgen Medical Information number: US sites, 1 - 800-77-AMGEN; Canadian sites, 
1-866-50-AMGEN; Amgen’s general number in the US, 1 -805-447-1000.  
Protocol  CONFIDENTIAL  
Labcorp Drug Development Study: 8493285  AMG 510 20220024  
18 May 2022  Page 3 of 69 
Internal Use Only Medical and Scientific Affairs  INVESTIGATOR AGREEMENT  
I have read the protocol en titled “An Open -label Study to Evaluate the Impact of Omeprazole, a 
Proton Pump Inhibitor, on the Pharmacokinetics of Sotorasib Coadministered with an Acidic 
Beverage  in Healthy Volunteers” and agree to conduct the study as described herein.  
I agree to com ply with the International Council for Harmonisation (ICH) Tripartite Guideline 
on Good Clinical Practice (GCP), Declaration of Helsinki, and applicable national or regional 
regulations/guidelines.  
I agree to ensure that the confidential information conta ined in this document will not be used for 
any purpose other than the evaluation or conduct of the clinical investigation without the prior 
written consent of Amgen Inc.  
 
_______________________________  
Signature  
 
_______________________________  ____________________________  
Name of Investigator  Date (DD Month YYYY)  
 
_______________________________  
Title and Role of Investigator  
 
_______________________________  
Institution Name  
 
_______________________________  
Address and Telephone Number of Institution  
_______________________________________  
Protocol  CONFIDENTIAL  
Labcorp Drug Development Study: 8493285  AMG 510 20220024  
18 May 2022  Page 4 of 69 
Internal Use Only Medical and Scientific Affairs  STUDY IDENTIFICATION  
Sponsor  Amgen Inc.  
One Amgen Center Drive  
Thousand Oaks, California 91320  
Sponsor’s Study Contact  , PhD  
Director, Clinical Pharmacology  
Amgen Inc.  
One Amgen Center Drive  
Thousand Oaks, California 91320  
Tel:
Email
Medical Monitor  , MD, PhD  
Medical Director  
Labcorp Drug Development  
3301 Kinsman Boulevard  
Madison, Wisconsin 53704  
Tel (Office): 
Tel (after hour s):
Email:
Sponsor’s Study Manager   
Global Early Clinical Development Manager  
Amgen Inc.  
One Amgen Center Drive  
Thousand Oaks, California 91320  
Tel:
Email:
Labcorp Project Manager   
3402 Kinsman Boulevard  
Madison, Wisconsin 53704  
Tel:
Email:
Statistician  , MS  
Senior Biostatistician  
Labcorp Drug Development  
3301 Kinsman Boulevard  
Madison, Wisc onsin 53704  
Tel:
Email:
 

Protocol  CONFIDENTIAL  
Labcorp Drug Development Study: 8493285  AMG 510 20220024  
18 May 2022  Page 5 of 69 
Internal Use Only Medical and Scientific Affairs  SYNOPSIS  
Title of study: An Open -label Study to Evaluate the Impact of Omeprazole, a Proton Pump 
Inhibitor, on the Pharmacokinetics of Sotorasib Coadministered with an Acidic Beverage  in 
Healthy Volunteers  
Objectives:  
The primary objective of the study is:  
 to evaluate the effects of omeprazole (a proton -pump inhibitor) and an acidic 
beverage ( Coca -Cola) on sotorasib pharmacokinetics (PK) when administered orally 
in healthy volunteers.  
The secondary objective of the study is:  
 to evaluate the safety and tolerability of sotorasib when coadministered with 
omeprazole and an acidic beverage  in healthy subjects . 
Study design:  
This will be a Phase 1, single -center (United States), open -label, fixed sequence study to 
investigate the effect of coadministration of omeprazole with an acidic beverage  on the PK of 
sotorasib in healthy male and female subjects.  After i nformed consent is obtained,  potential 
subjects will be screened to  assess their eligibility to enter the study within 28  days prior to the 
first dose administration. Subjects will be admitted into the Clinical Research Unit (CRU) on 
Day -1 and be confined  to the CRU until discharge/end of study (EOS) on Day  11. 
Subjects will receive a single dose of 960  mg sotorasib with 240  mL of water on Day  1, daily 
doses of 40  mg omeprazole with 240  mL of water on Days  4 to 8, and omeprazole and 
sotorasib with 240  mL o f an acidic beverage on Day  9. 
Number of subjects:  
Up to 14  subjects will be enrolled to ensure that 12 subjects complete the study.  
Diagnosis and main criteria for inclusion:  
Healthy male subjects or female subjects of nonchildbearing potential, 18 to 6 0 years of age 
(inclusive), and body mass index of 18 to 30  kg/m2 (inclusive).  
Investigational products, dose, and mode of administration:  
Amgen Investigational Medicinal Product: 960 mg sotorasib (8 x 120  mg tablets)  
Amgen Non -Investigational Medicinal Product: 40  mg omeprazole delayed release capsule  
 Day 1: 960  mg sotorasib administered orally with 240  mL of water after an overnight 
fast of at least 10  hours  
 Days 4 to 8: 40  mg omeprazole (delayed release capsule) administered orally with 
240 mL of water  once daily after an overnight fast of at least 10 hours  
 Day 9: 40  mg omeprazole (delayed release capsule) followed by 960  mg sotorasib 
administered orally within 5 minutes with 240  mL of an acidic beverage  after an 
overnight fast of at least 10  hours  
Duration of subject participation in the study:  
Planned Screening duration: approximately 4 weeks.  
Planned study duration (Screening to EOS): approximately 5.5 weeks.  
Protocol  CONFIDENTIAL  
Labcorp Drug Development Study: 8493285  AMG 510 20220024  
18 May 2022  Page 6 of 69 
Internal Use Only Medical and Scientific Affairs  Primary endpoints:  
The primary endpoints for this study are sotorasib PK parameters on Days 1 and 9: maximum 
observed plasma concentration (C max), area under the plasma concentration -time curve from 
time zero to infinity (AUC inf), and area under the plasma concentration -time curve from time 
zero to time of last quantifiable concentration (AU Clast). 
Secondary endpoints:  
The secondary endpoints for this study are adverse events, clinical laboratory tests, 12 -lead 
electrocardiograms, and vital signs.  
Statistical methods:  
The primary PK parameters are C max, AUC last, and AUC inf for sotorasib on D ays 1 and  9. A 
linear mixed -effects model will be used to analyze log -transformed primary PK parameters. 
The model assumes fixed effect for treatment and a random effect for subject. Geometric mean 
ratios for C max and AUC values and associated 90  confiden ce intervals (Test/Reference) will 
be estimated. The “Reference” treatment for PK analysis will be sotorasib administered alone 
with water, while the “Test” treatment will be omeprazole  coadministered with sotorasib and  
an acidic beverage . 
 
The number and percentage of subjects reporting any adverse events will be tabulated by 
Medical Dictionary for Regulatory Activities system organ class and preferred term. Tables of 
fatal adverse events, serious adverse events, adverse events leading to withdrawal from 
investigational product or other protocol -required therapies, and significant treatment -
emergent adverse events will also be provided. Subject -level data may be provided instead of 
tables if the subject incidence is low. Endpoints for clinical laboratory te sts, 
electrocardiograms, and vital signs will be summarized.  
Protocol  CONFIDENTIAL  
Labcorp Drug Development Study: 8493285  AMG 510 20220024  
18 May 2022  Page 7 of 69 
Internal Use Only Medical and Scientific Affairs  TABLE OF CONTENTS  
INVESTIGATOR AGREEME NT................................ ................................ ............................. 3 
STUDY IDENTIFICATION  ................................ ................................ ................................ .....4 
SYNOPSIS  ................................ ................................ ................................ ................................ .5 
TABLE OF CONTENTS  ................................ ................................ ................................ ........... 7 
LIST OF TABLES AND F IGURES ................................ ................................ ........................ 10 
LIST OF ABBREVIATION S ................................ ................................ ................................ ..11 
1. INTRODUCTION  ................................ ................................ ................................ ........... 13 
1.1. Background  ................................ ................................ ................................ ............ 13 
1.2. Pharmacokinetics  ................................ ................................ ................................ ...15 
1.3. Study Rationale  ................................ ................................ ................................ ......16 
1.4. Benefit -risk Assessment ................................ ................................ ......................... 17 
1.4.1.  Therapeutic Context  ................................ ................................ ..................... 17 
1.4.1.1.  Key Benefits ................................ ................................ ....................... 17 
1.4.1.2.  Risks  ................................ ................................ ................................ ...17 
2. OBJECTIVES AND ENDPO INTS  ................................ ................................ ................. 18 
2.1. Objectives  ................................ ................................ ................................ .............. 18 
2.2. Endpoints  ................................ ................................ ................................ ............... 19 
2.2.1.  Primary Endpoints  ................................ ................................ ....................... 19 
2.2.2.  Secondary Endpoints  ................................ ................................ ................... 19 
3. INVESTIGATIONAL PLAN  ................................ ................................ .......................... 19 
3.1. Overall Study Design and Plan  ................................ ................................ .............. 19 
3.2. Discussion of Study Design  ................................ ................................ ................... 20 
3.3. Selection of Doses in the Study  ................................ ................................ ............. 21 
4. SELECTION OF STUDY P OPULATION  ................................ ................................ .....21 
4.1. Inclusion Criteria  ................................ ................................ ................................ ...21 
4.2. Exclusion Criteria  ................................ ................................ ................................ ..21 
4.3. Screen Failures and Rescreening  ................................ ................................ ........... 24 
4.4. Subject Number and Identification  ................................ ................................ ........ 24 
4.5. Subject Withdrawal and Replacement  ................................ ................................ ...24 
4.6. Study Termination  ................................ ................................ ................................ .25 
4.7. Discontinuation of Study Treatment  ................................ ................................ ......25 
5. STUDY TREATMENTS  ................................ ................................ ................................ .26 
5.1. Investigational Product and Non -Investigational Products  ................................ ....26 
5.2. Treatment Overdose  ................................ ................................ ............................... 28 
5.3. Medical Devices ................................ ................................ ................................ .....28 
Protocol  CONFIDENTIAL  
Labcorp Drug Development Study: 8493285  AMG 510 20220024  
18 May 2022  Page 8 of 69 
Internal Use Only Medical and Scientific Affairs  5.4. Product Complaints  ................................ ................................ ................................ 28 
5.5. Randomization  ................................ ................................ ................................ .......28 
5.6. Blinding ................................ ................................ ................................ .................. 28 
5.7. Treatment Compliance  ................................ ................................ ........................... 28 
5.8. Drug Accountability ................................ ................................ ............................... 29 
6. CONCOMITANT THERAPIE S AND OTHER RESTRICT IONS  ................................ 29 
6.1. Concomitant Therapies  ................................ ................................ .......................... 29 
6.2. Diet ................................ ................................ ................................ ......................... 29 
6.3. Smoking  ................................ ................................ ................................ ................. 30 
6.4. Exercise  ................................ ................................ ................................ .................. 30 
6.5. Blood Donation  ................................ ................................ ................................ ......30 
7. STUDY ASSESSMENTS AN D PROCEDURES  ................................ ........................... 30 
7.1. Pharmacokinetic Assessments  ................................ ................................ ............... 31 
7.1.1.  Pharmacokinetic Blood Sample Collection and  Processing  ........................ 31 
7.1.2.  Analytical Methodology  ................................ ................................ .............. 31 
7.2. Safety and Tolerability Assessments  ................................ ................................ .....31 
7.2.1.  Adverse Events and Serious Adverse Events: Time Period and Frequency 
for Collecting and Reporting Safety Event Information  .............................. 31 
7.2.2.  Clinical Laboratory Evaluations  ................................ ................................ ..34 
7.2.3.  Vital Signs  ................................ ................................ ................................ ....34 
7.2.4.  12-Lead Electrocardiogram  ................................ ................................ ......... 35 
7.2.5.  Physical Examination ................................ ................................ ................... 35 
8. SAMPLE SIZE AND DATA  ANALYSIS  ................................ ................................ ......35 
8.1. Determination of Sample Size  ................................ ................................ ............... 35 
8.2. Analysis Populations  ................................ ................................ .............................. 35 
8.2.1.  Pharmacokinetic Population  ................................ ................................ ........ 35 
8.2.2.  Safety Population  ................................ ................................ ......................... 36 
8.3. Pharm acokinetic Analyses  ................................ ................................ ..................... 36 
8.4. Safety Analysis  ................................ ................................ ................................ ......36 
8.5. Interim Analysis  ................................ ................................ ................................ .....36 
9. REFERENCES  ................................ ................................ ................................ ................ 36 
10. APPENDICES  ................................ ................................ ................................ ................. 39 
Appendix  1: Safety Events: Definitions and Procedures for Recording, Evaluating, 
Follow -up, and Reporting of Adverse Events and Serious Adverse Events  .......... 40 
Appendix  2: Clinical Laboratory Evaluations  ................................ ................................ ...50 
Appendix  3: Total Blood Volume ................................ ................................ ...................... 52 
Protocol  CONFIDENTIAL  
Labcorp Drug Development Study: 8493285  AMG 510 20220024  
18 May 2022  Page 9 of 69 
Internal Use Only Medical and Scientific Affairs  Appendix  4: Contraception Requirements  ................................ ................................ ......... 53 
Appendix  5: Collection of Pregnancy and Lactation Information  ................................ .....54 
Appendix  6: Regula tory, Ethical, and Study Oversight Considerations  ............................ 58 
Appendix  7: Hepatotoxicity Stopping Rules: Suggested Actio ns and Follow -up 
Assessments  ................................ ................................ ................................ ........... 63 
Appendix  8: Schedule of Assessments  ................................ ................................ .............. 67 
 
Protocol  CONFIDENTIAL  
Labcorp Drug Development Study: 8493285  AMG 510 20220024  
18 May 2022  Page 10 of 69 
Internal Use Only Medical and Scientific Affairs  LIST OF TABLES AND FIGURES  
Table  1: Investigational Products and Non -Investigational Products  ...................... 27 
Table  2: Conditions for Withholding and/or Permanent Discontinuation of Amgen 
Investigational Product and Other Protocol -required Therapies Due to Potential 
Hepatotoxicity  ................................ ................................ ................................ .............. 61 
  
Figure  1: Study Schematic ................................ ................................ ......................... 20 
Figure  2:  Sample Serious Adverse Event Report Form  ................................ ............ 45 
Figure  3:  Pregnancy Notification Form  ................................ ................................ .....53 
Figure  4:  Lactation Notification Form  ................................ ................................ ......54 
 
Protocol  CONFIDENTIAL  
Labcorp Drug Development Study: 8493285  AMG 510 20220024  
18 May 2022  Page 11 of 69 
Internal Use Only Medical and Scientific Affairs  LIST OF ABBREVIATIONS  
Abbreviation  Definition  
ALP  alkaline phosphatase  
ALT  alanine aminotransferase  
AST  aspartate aminotransferase  
AV atrioventricular  
AUC  area under the plasma concentration -time curve  
AUC 0-24h area under the plasma concentration -time curve from time zero to 
24 hours postdose  
AUC inf area under the plasma concentration -time curve from time zero to 
infinity  
AUC last area under the plasma concentration -time curve from time zero to time 
of last quantifiable concentration  
BDC  bile duct cannulated  
CFR  Code of Federal Regulations  
Cmax maximum observed plasma concentration  
CRU  Clinical Research Unit  
CTCAE  Common Terminology Criteria for Adverse Events  
CV coefficient of variation  
CYP  cytochrome P450  
DILI  drug-induced liver injury  
ECG  electrocardiogram  
eCRF  electronic Case Report Form  
EDC  electronic data capture  
EOS  end of study  
FSH follicle -stimulating hormone  
GCP  Good Clinical Practice  
HR heart rate 
IB Investigator’s Brochure  
ICF Informed Consent Form  
ICH International Council for/Conference on Harmonisation  
ILD interstitial lung disease  
IMP investigational medicinal product  
INR international normalized ratio  
IRB Institutional Review Board  
Protocol  CONFIDENTIAL  
Labcorp Drug Development Study: 8493285  AMG 510 20220024  
18 May 2022  Page 12 of 69 
Internal Use Only Medical and Scientific Affairs  KRAS  Kirsten rat sarcoma viral oncogene homolog (protein)  
KRAS  Kirsten rat sarcoma viral oncogene homolog (gene)  
KRASG12C KRAS protein with a glycine to cysteine amino acid substitution at 
position 12  
KRAS 
p.G12C  KRAS  gene with a mutation resulting in  a glycine to cysteine amino 
acid substitution at position 12  
MATE  multidrug and toxic compound extrusion  
NSCLC  non-small cell lung cancer  
OATP  organic anion transporter  
P-gp P-glycoprotein  
PK pharmacokinetic(s)  
PPI proton pump inhibitor  
QD once daily  
QTcF  QT interval corrected for heart rate based on the Fridericia correction  
TBL  total bilirubin  
tmax time of the maximum observed concentration  
ULN  upper limit of normal  
USPI  United States Prescribing Information  
Vss volume of distribution at steady state  
 
Protocol  CONFIDENTIAL  
Labcorp Drug Development Study: 8493285  AMG 510 20220024  
18 May 2022  Page 13 of 69 
Internal Use Only Medical and Scientific Affairs  1. INTRODUCTION  
Refer to the Investigator’s Brochure (IB)1 for detailed information concerning the available 
pharmacology, toxicology, drug metabolism, clinical studies, and adverse event profile of the 
investigational medicinal product (IMP).  
1.1. Backgro und 
Investigational Medicinal Product  
The role of Kirsten rat sarcoma viral oncogene homolog (KRAS) gene mutations in human 
cancers has been known for decades;2 however, no anticancer therapies targeting KRAS 
mutations have been successfully developed. Thus, an unmet need exists for therapies that can 
specifically target cancers driven by KRAS  mutatio ns. Recent progress in the field suggests that 
1 mutant version of KRAS, KRAS p.G12C , which encodes the KRASG12C protein, might be 
tractable for small -molecule inhibition through a covalent interaction with the cysteine.3,4,5 
KRAS  p.G12C  mutation is a frequent mutation found in approximately 13  of lung 
adenocarcinoma (nonsquamous, non -small cell lung cancer [NSCLC]), 3  of colorectal cancer, 
and 1 to 2 of numero us other solid tumors.6,7,8 Sotorasib forms a specific covalent bond with 
the cysteine of KRASG12C, irreversibly locking the protein in an inactive conformation that 
cripples oncogenic signaling .5 As inactivation of KRAS has been demonstrated to inhibit cell 
growth and/or promote apoptosis selectively in tumor cells expressing KRAS  mutations ,9,10,11,3,4 
sotorasib may provide a therapeutic benefit for patients with KRAS p.G12C -driven cancers.  
The metabolism and excretion  of [14C]-sotorasib were evaluated in noncannulated male or 
female rats as well as in bile duct cannulated (BDC) male rats after a single oral dose of sotorasib 
(60 mg/kg). Overall, the data indicated that sotorasib was readily absorbed after an oral dose to 
noncannulated male and female rats and BDC male rats, underwent extensive biotransformation, 
and was eliminated primarily by nonenzymatic conjugation and metabolic clearance; 
[14C]-sotorasib -derived radioactivity was excreted primarily through biliary a nd fecal pathways. 
Biotransformation of sotorasib was mediated primarily by nonenzymatic glutathione 
conjugation, oxidation, and to a lesser extent, reduction, and dealkylation. Secondary sotorasib 
metabolism was substantive and included amide hydrolysis, cysteine -conjugate cleavage, 
N-acetylation, methylation, glucuronidation, and sulfonation. Biotransformation of sotorasib 
through primary glutathione conjugation was major and accounted for up to approximately 
21 to 33 of the dose from intact male and fe male rats, respectively, and up to approximately 
41 of the dose in male BDC rats. Sotorasib metabolites originating from primary oxidation 
account for up to approximately 20  of the dose in noncannulated rats and for approximately 
10 of the dose in BDC rats. Reduction of the sotorasib acrolein moiety account for up to 
approximately 10  of the dose in noncannulated male and female rats and approximately 2.7  
of the dose in BDC rats, whereas dealkylation at the piperazine moiety account ed for 
approximately 10  to 13 of the dose in noncannulated rats and for approximately 6  of the 
dose in BDC rats.  
Protocol  CONFIDENTIAL  
Labcorp Drug Development Study: 8493285  AMG 510 20220024  
18 May 2022  Page 14 of 69 
Internal Use Only Medical and Scientific Affairs  The metabolism and excretion of [14C]-sotorasib were evaluated in noncannulated male and 
female dogs after a single oral (500 mg/kg) dose of  sotorasib. Overall, [14C]-sotorasib -derived 
radioactivity was minimally absorbed and was eliminated predominantly as unchanged sotorasib 
in feces following a single 500 mg/kg dose to male or female dogs.  
Eight sotorasib clinical studies (20170543, 2019000 9, 20190135, 20190147, 20190172, 
20190288, 20190436, and 20190442) are currently ongoing in subjects with KRAS 
p.G12C -mutated tumors. In addition, a number of studies in healthy volunteers have explored the 
pharmacokinetics (PK) of sotorasib, including ass essments of mass -balance, food -effect, and 
various drug -drug interactions.  
Study 20170543 is an ongoing Phase 1/2, open -label, nonrandomized study evaluating the safety, 
tolerability, PK, pharmacodynamics, and efficacy of sotorasib in subjects with KRAS 
p.G12C -mutated NSCLC, colorectal cancer, and other solid tumors. As of 01  December  2020, 
456 subjects have been treated with sotorasib monotherapy across all doses (dose range: 180 to 
960 mg) and tumor types in the ongoing Phase  1 and Phase 2 treatment cohor ts. This includes 
359 subjects who were treated with the sotorasib dose of 960  mg once daily (QD) (fasted) for all 
tumor types.  
For the combination therapy cohorts, as of the data cutoff date (06 July 2020), a total of 
11 subjects with NSCLC were treated w ith sotorasib in combination with pembrolizumab in 
Part 1c/2c of Study  20170543. As of the data cutoff date (12 July 2021), a total of 41  subjects 
with KRAS p.G12C -mutated advanced solid tumors were treated with sotorasib in combination 
with trametinib in Study 20190135 Subprotocol A. As of the data cutoff date (12  July 2021), 
a total of 33 subjects with KRAS p.G12C -mutated advanced NSCLC were treated with sotorasib 
in combination with afatinib in Study 20190135 Subprotocol  D. As of the data cutoff date 
(12 July 2021), 44 subjects with KRAS p.G12C -mutated advanced solid tumors were treated with 
sotorasib and 39 subjects were treated with panitumumab in Study 20190135 Subprotocol  H. 
A summary of completed and ongoing clinical studies for sotorasib is provided  in the IB 
(Tables  6-1, 6-2, and 6 -3).1 In the United States and several other countries, sotorasib (960  mg 
daily) is currently approved for the treat ment of adult patients with KRAS  p.G12C -mutated 
locally advanced or metastatic NSCLC who have received at least 1  prior systemic therapy.  
Non-Investigational Medicinal Product  
Omeprazole is a proton pump inhibitor (PPI) indicated for the treatment of duode nal and gastric 
ulcers, heartburn and other symptoms associated with gastroesophageal reflux disease, 
maintenance of healing of erosive esophagitis, and long -term treatment of pathological 
hypersecretory conditions (eg, Zollinger -Ellison syndrome, multiple  endocrine adenomas, and 
systemic mastocytosis). Omeprazole inhibits gastric acid secretion and thereby increases the pH 
of the gastric environment, which may alter the absorption of some drugs with pH -dependent 
solubility and cause safety and efficacy con cerns.  Please refer to the United States Prescribing 
Information (USPI) for Prilosec (omeprazole) capsules for additional information.12 
Protocol  CONFIDENTIAL  
Labcorp Drug Development Study: 8493285  AMG 510 20220024  
18 May 2022  Page 15 of 69 
Internal Use Only Medical and Scientific Affairs  1.2. Pharmacokinetics  
The PK of sotorasib have been characterized in healthy subjects and in subjects with KRAS 
p.G12C -mutated solid tumors, including NSCLC. Sotorasib exhibited nonlinear, time -dependent, 
PK over the dose range of 180 to 960 mg (0.19 to 1 times  the approved recommended dosage) 
QD with similar systemic exposure (ie, area under the plasma concentration -time curve [AUC] 
from time zero to 24 hours postdose [AUC 0-24h] and maximum observed plasma concentration 
[Cmax]) across doses at steady state. Sot orasib systemic exposure was comparable between 
film-coated tablets and film -coated tablets predispersed in water administered under fasted 
conditions. Sotorasib plasma concentrations reached steady state within 22 days. No 
accumulation was observed after repeat sotorasib dosages with a mean accumulation ratio of 
0.56 (coefficient of variation [CV]: 59 ). 
Absorption  
The median time of the maximum observed concentration (t max) is 1 hour.  
Effect of Food  
When 960 mg sotorasib was administered with a high -fat, high-calorie meal (containing 
approximately 800 to 1000 calories with 150, 250, and 500 to 600 calories from protein, 
carbohydrate, and fat, respectively) in patients, sotorasib AUC 0-24h increased by 25  compared 
to administration under fasted conditions.  
Distribution  
The sotorasib mean apparent volume of distribution at steady state (V ss) is 211 L (CV: 135 ). 
In vitro, sotorasib plasma protein binding is 89 . 
Elimination  
The sotorasib mean terminal elimination half -life is 5 hours (standard deviation: 2). At 960  mg 
sotorasib QD, the sotorasib steady -state apparent clearance is 26.2 L/hr (CV: 76 ). 
Metabolism  
The main metabolic pathways of sotorasib are nonenzymatic conjugation and oxidative 
metabolism with cytochrome P450 (CYP)3As.  
Excretion  
After a single dose of radiolabeled sotorasib, 74  of the dose was recovered in feces (53  
unchanged) and 6  in urine (1  unchanged).  
Protocol  CONFIDENTIAL  
Labcorp Drug Development Study: 8493285  AMG 510 20220024  
18 May 2022  Page 16 of 69 
Internal Use Only Medical and Scientific Affairs  Specific Populations  
No clinically meaningful differences in the PK of sotorasib were observed based on age (28  to 
86 years), sex, race ( White, Black, and Asian), body weight (36.8  to 157.9 kg), line of therapy, 
Eastern Cooperative Oncology Group (0,  1), mild and moderate renal impairment (estimated 
glomerular filtration rate:  30 mL/min/1.73  m2), or mild hepatic impairment (aspartate 
amin otransferase [AST] or alanine aminotransferase [ALT]  2.5 x upper limit of normal [ULN] 
or total bilirubin  1.5 x ULN). The effect of severe renal impairment or moderate to severe 
hepatic impairment on sotorasib PK has not been studied. Study 20200326 is  currently ongoing 
to evaluate the PK of sotorasib in subjects with moderate or severe hepatic impairment.  
Drug -drug Interaction Studies  
Interactions of sotorasib with digoxin (P -glycoprotein [P -gp] substrate), metformin (multidrug 
and toxic compound extrusion [MATE]1 and MATE2 -K substrate), itraconazole (CYP3A4 and 
P-gp inhibitor), rifampin (organic anion transporter [OATP] 1B1/1B3 inhibitors and CYP3A4 
inducer), omeprazole (PPI), famotidine (histamine -2 receptor antagonist), and midazolam 
(CYP3A4 sub strate) are summarized in the IB (Table 6 -3).1 Overall,  these results suggest 
sotorasib may be taken safely with sensitive MATE1/2K substrates, CYP2D 6 substrates, strong 
CYP3A4/P -gp inhibitors, and strong OATP1B1/1B3 inhibitors. However, exposures of P -gp and 
sensitive CYP3A4 substrates may be altered.  
Coadministration of PPIs (such as omeprazole), histamine -2 receptor antagonists, and strong 
CYP3A4 in ducers may lead to decreased sotorasib exposure.  
1.3. Study Rationale  
The purpose of this study is to evaluate the effects of omeprazole, a PPI, on sotorasib PK when 
administered orally with  an acidic beverage  (Coca -Cola) and t o evaluate the safety and 
tolerability of sotorasib when coadministered with omeprazole and an acidic beverage  in healthy 
subjects.  
The concomitant use of sotorasib and acid -reducing agents was shown to decrease sotorasib 
exposures. Based on results from S tudy 20190320,1 geometric least -square mean ratios 
(test/reference) of sotorasib area under the plasma concentration -time curve from time zero to 
infinity (AUC inf) and C max were 0.582 and 0.431, respectively, when comparing sotorasib 
administered with omeprazole (test) and sotorasib administered alone (reference) in the fasted 
state. In Study 20200199,1 geometric least -square mean ratios of sotorasib AUC inf and C max were 
0.622  and 0.654, respectively, when comparing sotorasib coadministered with famotidine (test) 
and sotorasib alone (reference) under fed conditions. Geometric least -square mean ratios of 
sotorasib AUC inf and C max were 0.430  and 0.349, respectively, wh en comparing sotorasib 
coadministered with omeprazole (test) and sotorasib alone (reference) under fed conditions. 
These results suggest that concomitant administration of sotorasib with acid -reducing agents 
should be avoided.  
Protocol  CONFIDENTIAL  
Labcorp Drug Development Study: 8493285  AMG 510 20220024  
18 May 2022  Page 17 of 69 
Internal Use Only Medical and Scientific Affairs  The rationale for this study is to see if temporarily lowering gastric pH by adding a glass of an 
acidic beverage could reduce the extent of the interaction  between sotorasib  and concomitantly 
administered PPIs . Coca -Cola is the acidic beverage chosen for this study and has a pH of 
approximately 2.5 that can alter the acidity in the gastric environment and mitigate the impact of 
acid-reducing agents on the exposures of several compounds.13,14,15,16  
1.4. Benefit -risk Assessment  
The following benefit -risk assessment supports the conduct of this clinical study. Refer to the IB1 
for more information.  
1.4.1.  Therapeutic Context  
1.4.1.1.  Key Benefits  
Healthy subjects in the current study will not receive any health benefit (beyond that of an 
assessment of their medical status) from  participating in the study.  
1.4.1.2.  Risks  
To limit the risk of excessive exposure to healthy subjects in the current study, subjects will 
receive a single oral dose of 960  mg sotorasib administered as 8  x 120 mg tablets on Day  1, and 
960 mg sotorasib in combinati on with 40  mg omeprazole and an acidic beverage  on Day  9 
(details provided in  Section 3.3). 
Safety monitoring: During the study, subjects will be admi nistered all investigational product 
doses by site staff and will be instructed not to crush, chew, or split the sotorasib tablets or 
omeprazole when taking the dose under the supervision of the site staff. Safety assessments 
throughout the study include a dverse event monitoring, electrocardiograms (ECGs), physical 
examination, vital signs, and clinical laboratory evaluations.  
Risks of Sotorasib  
Based on sotorasib clinical trials experience, adverse drug reactions with sotorasib include 
diarrhea, nausea, fa tigue, vomiting, abdominal pain, increased liver enzymes, and interstitial lung 
disease (ILD)/pneumonitis. Based on nonclinical toxicity studies of sotorasib, potential safety 
concerns to be monitored in clinical studies of sotorasib include renal toxicity , anemia, and 
leukocytosis. Clinical signs and symptoms of these toxicities observed in clinical and nonclinical 
studies, along with relevant laboratory parameters, will be monitored during the study to ensure 
subjects’ safety.  
Abnormal Liver Function Test s 
Abnormal liver function tests (increased AST and increased ALT) have been observed in 
oncology subjects receiving sotorasib therapy. The events of abnormal liver function blood tests 
Protocol  CONFIDENTIAL  
Labcorp Drug Development Study: 8493285  AMG 510 20220024  
18 May 2022  Page 18 of 69 
Internal Use Only Medical and Scientific Affairs  generally resolved in subjects upon interruption of treatment.  The ris k mitigation plan consists 
of monitoring liver enzymes, with regular measurement of AST, ALT, alkaline phosphatase, and 
bilirubin to be performed. Specific eligibility for sotorasib, including baseline liver function, are 
provided in Section 4. 
Interstitial Lung Disease/Pneumonitis  
Interstitial lung disease/pneumonitis has occurred in patients treated with sotorasib with prior 
exposure to immunotherapy or radiotherapy. Incidence of ILD in clinical trials was 
approximately 0.8 . All events were serious and Grade 3 or 4 at onset, and 2 subjects 
discontinued sotorasib because of ILD/pneumonitis. During the study, subjects should be 
monitored f or new or worsening pulmonary symptoms. At any grade, immediately withhold 
sotorasib for suspected ILD/pneumonitis and permanently discontinue if ILD/pneumonitis is 
confirmed.  
As of 11 January 2022, no clinically meaningful sotorasib -related renal toxicity , anemia, 
leukocytosis, thyroid dysfunction, or splenomegaly has been observed. More detailed 
information about the key safety information of sotorasib, including a list of adverse drug 
reactions, may be found in the sotorasib IB and USPI.1,17 
Non-investigational Medicinal Product Risks  
Commonly reported adverse events for omeprazole include headache, abdominal pain, nausea, 
diarrhea, vomiting, and flatulence. Please refer to the package insert for commonly reported 
adverse events for omeprazole.12 
2. OBJECTIVES AND ENDPOINTS  
2.1. Objectives  
The primary objective of the study is:  
 to evaluate the effects of omeprazole (a PPI) and an acidic beverage  on sotorasib PK 
when administered orally in healthy volunteers.  
The secondary objective of the study is:  
 to evaluate safety and tolerability of sotorasib when coadministered with omeprazole 
and an acidic beverage  in healthy subjects.  
2.2. Endpoints  
2.2.1.  Primary Endpoints  
The primary endpoints of the study are sotorasib PK parameters on Days 1 and 9:  
Protocol  CONFIDENTIAL  
Labcorp Drug Development Study: 8493285  AMG 510 20220024  
18 May 2022  Page 19 of 69 
Internal Use Only Medical and Scientific Affairs   Cmax 
 AUC inf 
 area under the plasma concentration ‑time curve from time zero to time of last 
quantifiable concentration (AUC last) 
2.2.2.  Secondary Endpoints  
The secondary endp oints of the study are:  
 adverse events  
 clinical laboratory tests  
 12-lead ECGs  
 vital signs.  
3. INVESTIGATIONAL PLAN  
3.1. Overall Study Design and Plan  
This will be a Phase 1, single -center (United States), open -label, fixed sequence study to 
investigate the effect of coadministration of omeprazole with an acidic beverage  on the PK of 
sotorasib in healthy male and healthy female subjects. Up to 14 subjects will be enrolled to 
ensure that 12  subjects complete the study.  All subjects will receive each of the following  
treatments:  
 Day 1: 960 mg sotorasib (8  x 120 mg tablets) administered orally with 240  mL of water 
after an overnight fast of at least 10 hours  
 Days 4 to 8: 40  mg omeprazole (delayed release capsule) administered orally with 
240 mL of water QD  after an overnight fast of at least 10 hours  
 Day 9: 40 mg omeprazole (delayed release capsule) followed by 960  mg sotorasib 
(8 x 120 mg tablets)  administered orally within 5 minutes with 240  mL of an acidic 
beverage after an overnight fast of at least 10 hours.  
An o verview of the study design is shown in Figure  1. 
Protocol  CONFIDENTIAL  
Labcorp Drug Development Study: 8493285  AMG 510 20220024  
18 May 2022  Page 20 of 69 
Internal Use Only Medical and Scientific Affairs  Figure  1: Study Schematic  
 
Potential subjects will be screened to assess their eligibility to enter the study within 28  days 
prior to the first dose administration. Subjects will be admitted into the Clinical Research Unit 
(CRU) on Day  -1 and be confined to the CRU until discharge/end  of study (EOS) on Day  11. 
The total duration of study participation for each subject (from Screening through EOS visit) is 
anticipated to be approximately 5.5 weeks.  
The start of the study is defined as the date the first enrolled subject signs an Informed Consent 
Form (ICF). The  point of enrollment occurs at the time of subject number allocation. The end of 
the study is defined as the date of the last subject’s last assessment (scheduled or unscheduled).  
A Schedule of Assessments is presented in Appendix  8. 
3.2. Discussion of Study Design  
The fixed sequence design used in this study is typical for interaction studies where a relatively 
small number of subjects are required. This study  will be open -label because the study endpoints 
are not considered subjective.  
Omeprazole is a well -established PPI and has been used in clinical drug interaction studies.  
The proposed regimen for omeprazole in this study is to take omeprazole alone QD fo r 5 days 
followed by coadministration of omeprazole and sotorasib plus  an acidic beverage.  An acidic 
beverage  is expected to temporarily lower gastric pH. The 5 -day lead -in period is to maximize 
the antisecretory effect because the inhibition of acid secre tion increases with repeated QD 
dosing, reaching a plateau after 4 days.12 
Conducting the study in healthy subjects mitigates the potential confoundi ng effects of the 
disease state and concomitant medications.  
 
Protocol  CONFIDENTIAL  
Labcorp Drug Development Study: 8493285  AMG 510 20220024  
18 May 2022  Page 21 of 69 
Internal Use Only Medical and Scientific Affairs  3.3. Selection of Doses in the Study  
The approved dose level of sotorasib is 960 mg.14 There have been 6 clinical studies in healthy 
subjects where sotorasib has been administered at dose levels up to 960 mg and was well 
tolerated across the studies. In addition, there have been no dose -limiting toxicities observed 
with sotorasib monotherapy at 96 0 mg in subjects with advanced tumors with the 
KRAS  p.G612C  mutation. Please refer to the IB1 for more information.  
In this study, the 40  mg omeprazol e dose will be administered orally. This is a clinically 
recommended dose level and a dose level used to evaluate clinical drug interactions.  
4. SELECTION OF STUDY P OPULATION  
4.1. Inclusion Criteria  
Subjects must satisfy all of the following criteria prior to enro llment unless otherwise stated:  
1. Subject has provided informed consent before initiation of any study -specific 
activities/procedures.  
2. Healthy male or nonchildbearing female subjects, between 18 and 60 years of age 
(inclusive) at the time of Screening.  
3. In go od health, determined by no clinically significant findings from medical history, 
physical examination, 12 -lead ECGs, vital signs measurements, and clinical laboratory 
evaluations (congenital nonhemolytic hyperbilirubinemia [eg, suspicion of Gilbert’s 
synd rome based on total and direct bilirubin] is not acceptable) as assessed by the 
Investigator (or designee).  
4. Body mass index between 18 and 30 kg/m2 (inclusive) at the time of Screening.  
5. Females must be of nonchildbearing potential, defined as permanently sterile (ie, due to 
hysterectomy, bilateral salpingectomy, or bilateral oophorectomy) or postmenopausal 
(defined as at least 45 years of age with amenorrhea for 12 months without an alter native 
medical cause and follicle -stimulating hormone [FSH] level  40 mIU/mL).  
4.2. Exclusion Criteria  
Subjects will be excluded from the study if they satisfy any of the following criteria prior to 
enrollment unless otherwise stated:  
1. History or evidence, at S creening or Check -in, of clinically significant disorder, 
condition, or disease not otherwise excluded that, in the opinion of the Investigator (or 
designee), would pose a risk to subject safety or interfere with the study evaluation, 
procedures, or comple tion. 
Protocol  CONFIDENTIAL  
Labcorp Drug Development Study: 8493285  AMG 510 20220024  
18 May 2022  Page 22 of 69 
Internal Use Only Medical and Scientific Affairs  2. History or evidence of clinically significant arrhythmia at Screening, including any 
clinically significant findings on the ECG taken at Check -in. 
3. A QT interval corrected for heart rate (HR) based on the Fridericia correction (QTcF) 
interval  450 ms ec in male subjects or  470 msec in female subjects or history/evidence 
of long QT syndrome; and/or PR interval  200 msec, second degree atrioventricular 
(AV) block or third degree AV block, at Screening or Check -in. Electrocardiograms will 
be taken as s ingle ECGs.  If parameters are out -of-range, the site will collect 2 more 
ECGs and then calculate the mean to determine eligibility.  
4. Systolic blood pressure  140 mmHg or  90 mmHg, or diastolic blood pressure 
 90 mmHg, or HR  100 bpm, at Screening or Ch eck-in. Subjects with out -of-range 
values that are not clinically significant (as determined by the Investigator) may have the 
test repeated once during Screening or Check -in (within 1 hour of original assessment) 
and the subject may be enrolled if a repea ted value is within normal range.  
5. History suggestive of achlorhydria, esophageal (including esophageal spasm, 
esophagitis), gastric, or duodenal ulceration or bowel disease (including, but not limited 
to, peptic ulceration, gastrointestinal bleeding, ulcerative colitis, Crohn’s disease, or 
irritable bowel syndrome), or a history of gastrointestinal surgery other than 
uncomplicated appendectomy.  
6. Inability to swallow oral medication or history of malabsorption syndrome.  
7. History of hypersensitivity, intol erance, or allergy to any drug compound, food, or other 
substance, unless approved by the Investigator (or designee) and in consultation with the 
Sponsor.  
8. Poor peripheral venous access.  
9. Estimated glomerular filtration rate less than 70 mL/min/1.73 m2 as ca lculated by the  
CKD -EPI Creatinine Equation18, at Screening or Check -in. Subjects with out -of-range 
values may have the test repeated once at the discretion of the Investigator.  
10. ALT or AST should be ULN at Screening or Check -in (for these parameters, a su bject 
with out -of-range values may have the tests repeated once and the subject may be 
enrolled if the repeated values are ULN or if the repeated values above ULN are 
deemed not clinically significant by the Investigator [eg, 1.5 x ULN]).  
11. Positive hepatit is B or hepatitis C panel and/or positive human immunodeficiency virus 
test at Screening. Subjects whose results are compatible with prior immunity (vaccination 
or prior infection) may be included.  
12. Use of any over -the-counter or prescription medications wi thin 30 days or 5 half -lives 
(whichever is longer) before enrollment, unless deemed acceptable by the Investigator (or 
designee) and in consultation with the Sponsor.  
a. Acetaminophen [paracetamol] (up to 2 g per day) for analgesia will be allowed.  
Protocol  CONFIDENTIAL  
Labcorp Drug Development Study: 8493285  AMG 510 20220024  
18 May 2022  Page 23 of 69 
Internal Use Only Medical and Scientific Affairs  13. All herbal  medicines (eg, St. John’s wort), vitamins, and supplements consumed by the 
subject within the 30 days prior to enrollment, unless deemed acceptable by the 
Investigator (or designee) and in consultation with the Sponsor.  
14. Consumption of foods and beverages containing poppy seeds, grapefruit, or Seville 
oranges within 7 days prior to Check -in.  
15. History of alcoholism or drug/chemical abuse within 1 year prior to Check -in. 
16. Alcohol consumption from 48 hours prior to Check -in. 
17. Regular alcohol consumption of  14 units per week for males and  7 units per week for 
females. One unit of alcohol equals 12  oz (360 mL) beer, 1½ oz (45 mL) liquor, or 5  oz 
(150 mL) wine.  
18. Use of tobacco - or nicotine -containing products within 6 months prior to Check -in. 
19. Positive test for illicit drugs, cotinine (tobacco or nicotine use) at Screening or Check -in 
and/or alcohol use at Check -in only.  
20. Consumption of caffeine -containing foods and beverages within 48 hours prior to 
Check -in. 
21. Female subjects with a positive pregnancy test at Scre ening or Check -in. 
22. Female subjects lactating/breastfeeding or who plan to breastfeed during the study 
through 7 days after the EOS.  
23. Unwilling to adhere to contraceptive requirements through 7 days after the EOS (see  ).  
24. Unwilling to abstain from sperm donation through 7 days after the EOS (see ). 
25. Male subjects with a female partner of childbearing potential and not willing to inform 
his partner of his participation in this clinical study.  
26. Male subjects with a pregnant partner or partner planning to become pregnant who are 
unwilling to practice abstine nce (refrain from heterosexual intercourse) or use 
contraception while the subject is on study through 7 days after the EOS.  
27. Subject has received a dose of an investigational drug within the past 30 days or 
5 half-lives, whichever is longer, prior to Check -in. 
28. Have previously completed or withdrawn from this study or any other study investigating 
sotorasib or have previously received the investigational product.  
29. Donation of blood from 90 days prior to Check -in, plasma from 2 weeks prior to 
Check -in, or pla telets from 6 weeks prior to Check -in. 
30. Receipt of blood products within 2 months prior to Check -in.  
31. Unwilling to abide with study restrictions.  
32. Subjects who, in the opinion of the Investigator (or designee), should not participate in 
this study.  
Protocol  CONFIDENTIAL  
Labcorp Drug Development Study: 8493285  AMG 510 20220024  
18 May 2022  Page 24 of 69 
Internal Use Only Medical and Scientific Affairs  33. Performed  strenuous exercise, began a new exercise program, or participated in any 
unusually strenuous physical exertion within 7 days prior to Check -in. 
4.3. Screen Failures and Rescreening  
Screen failures are defined as subjects who consent to participate in the clini cal study but are not 
subsequently enrolled in the study because they do not meet eligibility requirements. A minimal 
set of screen failure information will be collected that includes demography, screen failure 
details, eligibility criteria, medical histor y, prior therapies, and any serious adverse events.  
Individuals who do not meet the criteria for participation in this study (screen failure) may be 
rescreened only once.  
4.4. Subject Number and Identification  
Subjects will have a unique identification number used at Screening. Subjects will be assigned a 
subject number prior to the first dosing occasion. Assignment of subject numbers will be in 
ascending order and no numbers will be omitted (eg,  Subjects  0101, 0102, 0103). Replacement 
subjects will be assigned  a subject number corresponding to the number of the subject he/she is 
replacing plus 1000 (eg,  Subject  1101 replaces Subject  0101).  
Subjects will be identified by subject number only on all study documentation. A list identifying 
the subjects by subject n umber will be kept in the Site Master File.  
4.5. Subject Withdrawal and Replacement  
A subject is free to withdraw from the study at any time. In addition, a subject will be withdrawn 
from dosing if any of the following criteria are met:  
 change in compliance wit h any inclusion/exclusion criterion that is clinically relevant and 
affects subject safety as determined by the Investigator (or designee)  
 noncompliance with the study restrictions that might affect subject safety or study 
assessments/objectives, as consid ered applicable by the Investigator (or designee)  
 occurrence of any Common Terminology Criteria for Adverse Events (CTCAE) v5.0 
Grade 3 adverse event  
 occurrence of Grade 2 adverse event considered by the Investigator (or designee) to be at 
least possibly related to sotorasib and, in the opinion of the Investigator (or designee), 
warrants subject withdrawal (eg, neuropathy, chronic diarrhea, etc)  
 any clinically relevant sign or symptom that, in the opinion of the Investigator (or 
designee), warrants subject  withdrawal.  
If 2 or more subjects are withdrawn from the study due to adverse events that are considered by 
the Investigator to be at least possibly related to sotorasib or if there is 1 Grade 3 event, dosing 
Protocol  CONFIDENTIAL  
Labcorp Drug Development Study: 8493285  AMG 510 20220024  
18 May 2022  Page 25 of 69 
Internal Use Only Medical and Scientific Affairs  will be paused, and the Investigator and Spons or will convene to review the data and determine 
the next step.  
If a subject is withdrawn from dosing, the Sponsor (or designee) will be notified and the date and 
reason(s) for the withdrawal will be documented in the subject’s electronic Case Report Form 
(eCRF). If a subject is withdrawn, efforts will be made to perform all EOS assessments, if 
possible ( Appendix  8). Other procedures may be performed at t he Investigator’s (or designee’s) 
and/or Sponsor’s discretion. If the subject is in -house, these procedures should be performed 
before the subject is discharged from the clinic. The Investigator (or designee) may also request 
that the subject return for an  additional follow -up visit. All withdrawn subjects will be followed 
until resolution of all their adverse events, or until the unresolved adverse events are judged by 
the Investigator (or designee) to have stabilized.  
Subjects who are withdrawn for reason s not related to study drug may be replaced following 
discussion between the Investigator and the Sponsor. Subjects withdrawn as a result of adverse 
events/serious adverse events thought to be related to the study drug will generally not be 
replaced.  
4.6. Study  Termination  
The Sponsor may stop the study or study site participation in the study for medical, safety, 
regulatory, administrative, or other reasons consistent with applicable laws, regulations, and 
Good Clinical Practice. Both the Sponsor and the Inves tigator reserve the right to terminate the 
Investigator's participation in the study according to the Clinical Trial Agreement. The 
Investigator is to notify the Institutional Review Board (IRB) in writing of the study's completion 
or early termination and  send a copy of the notification to the Sponsor. The Sponsor reserves the 
unilateral right, at its sole discretion, to determine whether to supply investigational product and 
by what mechanism, after termination of the study.  
In addition, the study may be  terminated by the Sponsor at any time and for any reason. If the 
Sponsor decides to terminate the study, they will inform the Investigator as soon as possible.  
4.7. Discontinuation of Study Treatment  
Subjects (or a legally acceptable representative) can declin e to continue receiving investigational 
product and/or other protocol -required therapies or study procedures at any time during the study 
but continue participation in the study. If this occurs, the Investigator is to discuss with the 
subject the appropria te processes for discontinuation from investigational product or other 
protocol -required therapies and must discuss with the subject the possibilities for continuation of 
the Schedule of Assessments ( Appendix  8) including different options of follow -up (eg, in 
person, by phone/mail, through family/friends, in correspondence/communication with other 
treating physicians, from the review of medical records) a nd collection of data, including 
endpoints, adverse events, serious adverse events, and must document this decision in the 
subject’s medical records. Subjects who have discontinued investigational product and/or other 
protocol -required therapies or study p rocedures should not be automatically removed from the 
Protocol  CONFIDENTIAL  
Labcorp Drug Development Study: 8493285  AMG 510 20220024  
18 May 2022  Page 26 of 69 
Internal Use Only Medical and Scientific Affairs  study. Whenever safe and feasible, it is imperative that subjects remain on study to ensure safety 
surveillance and/or collection of outcome data.  
Reasons for removal from protocol -required investigati onal product(s) or procedural assessments 
include any of the following:  
 Decision by the Sponsor  
 Lost to follow -up 
 Death  
 Protocol deviation  
 Noncompliance  
 Adverse events  
 Subject request  
 Pregnancy.  
5. STUDY TREATMENTS  
Study treatment is defined as any investigational product, non -investigational product, placebo, 
combination product, or medical device intended to be administered to a study subject according 
to the study protocol.  
Note that in several countries, investigational product and non -investigat ional product are 
referred to as IMP and non -IMP, respectively.  
5.1. Investigational Product and Non -Investigational Products  
The IMP will be supplied by the Sponsor. The Investigational Product Instruction Manual, a 
document external to this protocol, contains  detailed information regarding the storage, 
preparation, destruction, and administration of the IMP shown in Table  1. 
The Investigator will commercially source the non -IMP shown in Table  1. The non -IMP will b e 
stored according to the manufacturer’s instructions.  
All supplies of investigational product, both bulk and subject -specific, will be stored in 
accordance with the manufacturer’s instructions or pharmacy instructions. Until dispensed to the 
subjects, the  investigational products will be stored at the study site in a location that is locked 
with restricted access.  
Protocol  CONFIDENTIAL  
Labcorp Drug Development Study: 8493285  AMG 510 20220024  
18 May 2022  Page 27 of 69 
Internal Use Only Medical and Scientific Affairs  Table  1: Investigational Products and Non -Investigational Products  
Study Treatment 
Name  Amgen Investigational  
Medic inal Product:  
 Sotorasib (AMG 510)  Non-Amgen Investigational 
Medicinal  Product:  
Omeprazole  
Unit Strength and 
Formulation  120 mg tablet  40 mg delayed release capsule  
Dosage Level  960 mg (8 x 120  mg tablets)  40 mg (1 x 40  mg capsule)  
Route of 
Administration  Oral Oral 
Accountability  The quantity administered, date 
administered, and lot number of 
investigational product are to be 
recorded on each subject's electronic 
Case Report Form.  The quantity administered, date 
administered, and lot number  of 
non-investigational product are to be 
recorded on each subject's electronic 
Case Report Form.  
Dosing Instructions  The Investigator/designee will 
administer the treatment after the 
completion of all predose procedures.  
Day 1 : Eight tablets will be 
administered with 8  ounces (240  mL) 
of water after an overnight fast of at 
least 10  hours. No food will be given 
for at least 4 hours postdose.  
Day 9 : Omeprazole will be 
administered followed by 960 mg 
sotorasib within 5  minutes. 
Omeprazole and sotorasib will be 
taken with 8  ounces (240  mL) of an 
acidic beverage ( Coca -Cola after 
an overnight fast of at least 10 hours. 
No food will be given for at least 
4 hours post sotorasib administration.  The Investigator/designee will 
administe r the treatment after the 
completion of all predose 
procedures.  
Days 4 to 8 : One capsule will be 
administered with 8 ounces 
(240 mL) of water after an overnight 
fast of at least 10  hours.  
Day 9 : Omeprazole will be 
administered followed by 960 mg 
sotorasib within 5 minutes. 
Omeprazole and sotorasib will be 
taken with  8 ounces (240 mL) of  an 
acidic beverage  (Coca -Cola) after 
an overnight fast of at least 10  hours. 
No food will be given for at least 4 
hours post sotorasib administration.  
Note: Only Coca -Cola will be consumed with omeprazole and sotorasib on Day 9.  
Except as part of the dose administration, subjects will restrict their consumption of water for 
1 hour prior to dosing and for 2 hours after dosing; at all other times during the study, subjects 
may consume water as desired. No food will be given for at least 4 hours post sotorasib 
administration.  
Subjects will be dosed while standing and will not be permitted to lie supine for 2 hours after 
administration of IMP and non -IMP, except as necessitated  by the occurrence of an adverse 
event(s) and/or study procedures.  
Protocol  CONFIDENTIAL  
Labcorp Drug Development Study: 8493285  AMG 510 20220024  
18 May 2022  Page 28 of 69 
Internal Use Only Medical and Scientific Affairs  5.2. Treatment Overdose  
The effects of overdose of sotorasib are not known. In case of overdose, consultation with the 
medical monitor is recommended for prompt reporting of clinically apparent or laboratory 
adverse events possibly related to over dosage, and to discuss further management of the subject.  
5.3. Medical Devices  
No investigational medical device(s) will be used in this study. Other non -investigational 
medical devices may be used in the co nduct of this study as part of standard care. Non -Amgen 
non-investigational medical devices (eg, syringes, sterile needles) that are commercially 
available are not usually provided or reimbursed by the Sponsor (except, for example, if required 
by local reg ulation). The Investigator will be responsible for obtaining supplies of these devices.  
5.4. Product Complaints  
A product complaint is any written, electronic, or oral communication that alleges deficiencies 
related to the identity, quality, durability, reliabi lity, safety, effectiveness, or performance of a 
drug(s) or device(s) after it is released for distribution to market or clinic by either (1) Sponsor or 
(2) distributors or partners for whom the Sponsor manufactures the material. This includes all 
componen ts distributed with the drug, such as packaging drug containers, delivery systems, 
labeling, and inserts. This includes any IMP (sotorasib) and non -IMP (omeprazole) provisioned 
and/or repackaged/modified by the Sponsor.  
Any product complaint(s) associated with an IMP supplied by the Sponsor are to be reported 
according to the instructions provided in the Amgen Investigational Product Information Manual.  
5.5. Randomization  
This is a nonrandomized study. The study has a fixed treatment sequence.  
5.6. Blinding  
This is an open -label study.  
5.7. Treatment Compliance  
The following measures will be employed to ensure treatment compliance:  
 All doses  of sotorasib and omeprazole  will be administered under the supervision of 
suitably qualified study site staff.  
 Immediately after dose administration, visual inspection of the mouth and hands will be 
performed for each subject.  
Protocol  CONFIDENTIAL  
Labcorp Drug Development Study: 8493285  AMG 510 20220024  
18 May 2022  Page 29 of 69 
Internal Use Only Medical and Scientific Affairs   At each dosing occasion, a predose and postdose inventory of sotorasib and omeprazole  
will be performed.  
5.8. Drug Accountability  
The Investigator (or designee) will maintain an accurate record of the receipt of sotorasib tablets 
received. In addition, an accurate drug disposition record will be kept, specifying the amount 
dispensed to each subject and the date of dispensing. This drug accountability record will b e 
available for inspection at any time. At the completion of the study, the original drug 
accountability record will be available for review by the Sponsor upon request.  
For each batch of unit doses, the empty used unit dose containers will be discarded up on 
satisfactory completion of the compliance and accountability procedures. Any unused assembled 
unit doses will be retained until completion of the study.  
At the completion of the study, all unused sotorasib tablets will be returned to the Sponsor, 
retain ed at the study site, or disposed of by the study site, per the Sponsor’s written instructions.  
Omeprazole will also be subject to accountability procedures, and the CRU staff will destroy 
unused supplies of omeprazole per the Sponsor’s written instruction s. 
6. CONCOMITANT THERAPIES AND OTHER RESTRICTIONS  
6.1. Concomitant Therapies  
Subjects will refrain from use of any prescription or nonprescription medications/products during 
the study until the EOS visit, unless the Investigator (or designee) and/or Sponsor have  given 
their prior consent.  
Paracetamol/acetaminophen (2 g/day) are acceptable concomitant medications. The 
administration of any other concomitant medications during the study is prohibited without prior 
approval of the Investigator (or designee), unless its use is deemed necessary for treatment of an 
adverse event/serious adverse event. Any medication taken by a subject during the course of the 
study and the reason for its use will be documented in the source data.  
6.2. Diet 
Subjects will be fasted overnight ( at least 8  hours) before collection of blood samples for clinical 
laboratory evaluations. While confined at the study site, subjects will receive a standardized diet 
at scheduled times that do not conflict with other study -related activities.  
Refer to Section 5 and Table  1 for diet requirements/restricti ons on applicable days of study 
treatment and/or PK assessments.  
Protocol  CONFIDENTIAL  
Labcorp Drug Development Study: 8493285  AMG 510 20220024  
18 May 2022  Page 30 of 69 
Internal Use Only Medical and Scientific Affairs  Foods and beverages containing poppy seeds, grapefruit, or Seville oranges will not be allowed 
from 7 days prior to Check -in until EOS.  
Caffeine -containing foods and beverages will not be all owed from 48  hours before Check -in 
until the EOS visit, with the exception of the Day 9 visit (dosing plus  an acidic beverage ). 
Consumption of alcohol will not be permitted from 48 hours prior to Check -in until the EOS 
visit.  
6.3. Smoking  
Subjects will not be permitted to use tobacco - or nicotine -containing products within 6  months 
prior to Check -in until the EOS  visit.  
6.4. Exercise  
Subjects are required to refrain from strenuous exercise from 7 days before Check -in until EOS. 
Subjects will otherwise maintain their  normal level of physical activity during this time (ie, will 
not begin a new exercise program nor participate in any unusually strenuous physical exertion).  
6.5. Blood Donation  
Subjects are required to refrain from donation of blood from 90 days prior to Check -in, plasma 
from 2 weeks prior to Check -in, and platelets from 6 weeks prior to Check -in until 90 days after 
the EOS.  
7. STUDY ASSESSMENTS AND PROCEDURES  
Every effort will be made to schedule and perform the procedures as closely as possible to the 
nominal ti me, giving considerations to appropriate posture conditions, practical restrictions, and 
the other procedures to be performed at the same timepoint.  
The highest priority procedures will be performed closest to the nominal time. The order of 
priority for s cheduling procedures around a timepoint is (in descending order of priority):  
 dosing  
 PK blood samples  
 safety assessments (ECGs will be scheduled before vital signs measurements)  
 any other procedures.  
Where activities at a given timepoint coincide, consideration must be given to ensure that the 
following order of activities is maintained: ECGs, vital signs, safety laboratory assessments, and 
assessment of adverse events and serious adverse events.  
Protocol  CONFIDENTIAL  
Labcorp Drug Development Study: 8493285  AMG 510 20220024  
18 May 2022  Page 31 of 69 
Internal Use Only Medical and Scientific Affairs  7.1. Pharmacokinetic Assessments  
7.1.1.  Pharmacokinetic Blood Sam ple Collection and Processing  
Blood samples (approximately 1 x 4 mL for sotorasib) will be collected by venipuncture or 
cannulation at the times indicated in the Schedule of Assessments in Appendix  8. Procedures for 
collection, processing, and shipping of PK blood samples will be detailed in a separate 
document.  
Any blood sample collected according to the Schedule of Assessments ( Appendix  8) can be 
analyzed for any of the tests outlined in the protocol and for any tests necessary to minimize 
risks to study subjects. This includes testing to ensure analyt ical methods produce reliable and 
valid data throughout the course of the study. This can also include, but is not limited to, 
investigation of unexpected results, incurred sample reanalysis, and analyses for method transfer 
and comparability.  
7.1.2.  Analytical M ethodology  
Plasma concentrations of sotorasib will be determined using validated analytical procedures. 
Specifics of the analytical method will be provided in a separate document.  
7.2. Safety and Tolerability Assessments  
7.2.1.  Adverse Events and Serious Adverse Event s: Time Period and Frequency for 
Collecting and Reporting Safety Event Information  
Adverse event definitions, assignment of severity and causality, and procedures for reporting 
adverse events and serious adverse events are detailed in Appendix  1. 
The condition of each subject will be monitored from the time of signing the ICF to EOS. If an 
event is reported as beginning prior to sig ning of the ICF or occurs prior to initiation of study 
treatment on Day  1 and is assessed as not related to study procedures by the Investigator (or 
designee), the event will be recorded as subject medical history. If an event occurs after signing 
of the I CF but prior to initiation of study drug and the event is considered serious (regardless of 
causality to procedure), the event will be recorded as a serious adverse event.  
Any events occurring after study drug administration on Day 1 through EOS will be re ported as 
adverse events. Subjects will be observed for any signs or symptoms and asked about their 
condition by open questioning, such as “How have you been feeling since you were last asked?”, 
at least once each day while resident at the study site and a t each study visit. Subjects will also be 
encouraged to spontaneously report adverse events and serious adverse events occurring at any 
other time during the study.  
Adverse Events  
Protocol  CONFIDENTIAL  
Labcorp Drug Development Study: 8493285  AMG 510 20220024  
18 May 2022  Page 32 of 69 
Internal Use Only Medical and Scientific Affairs  The adverse event grading scale to be used in this study is described in Appendix  1. 
The Investigator is responsible for ensuring that all adverse events observed by the Investigator 
or reported by the subject (whether reported  by the subject voluntarily or upon questioning or 
noted on physical examination) from the first dose of study drug through the EOS visit are 
recorded/reported using the appropriate eCRF.  
Serious Adverse Events  
The Investigator is responsible for ensuring that all serious adverse events observed by the 
Investigator or reported by the subject that occur after signing of the ICF through 30 days after 
the last dose of study treatment or the EOS visit (whichever is later) are reported using the 
appropriate eCRF  and reported on the paper -based Serious Adverse Event Report Form 
(described in Appendix  1). 
All serious adverse events will be collected, recorded, a nd reported to the Sponsor within 
24 hours of the Investigator’s awareness of the event. The Investigator will submit any updated 
serious adverse event data to the Sponsor within 24 hours of it being available.  
Since the criteria for the CTCAE grading scal e differs from the regulatory criteria for serious 
adverse events, if adverse events correspond to Grade 4 CTCAE toxicity grading scale criteria 
(eg, laboratory abnormality reported as Grade 4 without manifestation of life -threatening status), 
it will be l eft to the Investigator’s judgment to also report these abnormalities as serious adverse 
events. For any adverse event that applies to this situation, comprehensive documentation of the 
event’s severity must be recorded in the subject medical records.  
Serious Adverse Events After the Protocol -Required Reporting Period  
After EOS, there is no requirement to actively monitor study subjects after the study has ended 
with regards to study subjects treated by the Investigator. However, if the Investigator become s 
aware of serious adverse events suspected to be related to investigational product, then these 
serious adverse events will be reported to the Sponsor within 24 hours following the 
Investigator’s awareness of the event.  
Serious adverse events reported out side of the protocol -required reporting period will be 
captured within the Sponsor’s safety database as clinical trial cases and handled accordingly 
based on the relationship to investigational product.  
If further safety -related data are needed to fulfill any regulatory reporting requirements for a 
reportable event, then additional information may need to be collected from the subject’s records 
after the subject ends the study.  
Method of Detecting Adverse Events and Serious Adverse Events  
Protocol  CONFIDENTIAL  
Labcorp Drug Development Study: 8493285  AMG 510 20220024  
18 May 2022  Page 33 of 69 
Internal Use Only Medical and Scientific Affairs  Care will be take n not to introduce bias when detecting adverse events and/or serious adverse 
events. Open -ended and non -leading verbal questioning of the subject is the preferred method to 
inquire about adverse event occurrence.  
Follow -up of Adverse Events and Serious Adv erse Events  
After the initial adverse event/serious adverse event report, the Investigator is required to 
proactively follow each subject at subsequent visits/contacts. All adverse events and serious 
adverse events will be followed, where possible, until resolution, stabilization, until the event is 
otherwise explained, or the subject is lost to follow -up. This will be completed at the 
Investigator’s (or designee’s) discretion.  
All new information for previously reported serious adverse events must be sent  to Amgen 
within 24 hours following knowledge of the new information. If specifically requested, the 
Investigator may need to provide additional follow -up information, such as discharge summaries, 
medical records, or extracts from the medical records. Info rmation provided about the serious 
adverse event must be consistent with that recorded on the eCRF.  
Regulatory Reporting Requirements for Serious Adverse Events  
If a subject is permanently withdrawn from protocol -required therapies because of a serious 
adverse event, this information must be submitted to the Sponsor.  
Prompt notification by the Investigator to the Sponsor of serious adverse events is essential so 
that legal obligations and ethical responsibilities towards the safety of subjects and the safet y of a 
study treatment under clinical investigation are met.  
The Sponsor has a legal responsibility to notify both the local regulatory authority and other 
regulatory agencies about the safety of a study treatment under clinical investigation. The 
Sponsor will comply with country -specific regulatory requirements relating to safety reporting to 
the regulatory authority, IRBs, and Investigators.  
Individual safety reports must be prepared for suspected unexpected serious adverse reactions 
according to local re gulatory requirements and Sponsor policy and forwarded to Investigators as 
necessary.  
An Investigator who receives an individual safety report describing a serious adverse event or 
other specific safety information (eg, summary or listing of serious advers e events) from the 
Sponsor will file it along with the IB and will notify the IRB, if appropriate according to local 
requirements.  
Safety Monitoring Plan  
Subject safety will be routinely monitored as defined in the Sponsor’s safety surveillance and 
signal management processes.  
Protocol  CONFIDENTIAL  
Labcorp Drug Development Study: 8493285  AMG 510 20220024  
18 May 2022  Page 34 of 69 
Internal Use Only Medical and Scientific Affairs  Pregnancy and Lactation  
Details of all pregnancies and/or lactation in female subjects and pregnancies in female partners 
of male subjects will be collected after the start of the study treatment until 7 days after EOS.  
If a pregnancy  is reported, the Investigator is to inform Amgen within 24 hours of learning of the 
pregnancy and/or lactation and is to follow the procedures outlined in  Appendix  5. Amgen 
Global Patient Safety will follow -up with the Investigator regarding additional information that 
may be requested.  
Abnormal pregnancy outcomes (eg, spontaneous abortion, fetal death, stillbirth, congenital 
anomalies, ectopic pregnancy)  are considered serious adverse events.  
Further details regarding pregnancy and lactation are provided in Appendix  5. 
7.2.2.  Clinical Laboratory Evaluations  
Blood and urine samples will be collected for clinical laboratory evaluations (including clinical 
chemistry, hematology, urinalysis, and serology) at the times indicated in the Schedule of 
Assessments in Appendix  8. Clinical laboratory evaluations are listed in  Appendix  2. 
The Investigator is responsible for reviewing laboratory test results and recording any clinically 
relevant changes occurring during the study in the Case Report Form/eCRF. The Investigator 
must determine whether an abnormal value in an individual study subject represents a clinically 
significant change from the subject’s baseline values. In general, abnormal laboratory findings 
without clinical significance (based on the Investigator’s judgement) are not to be recorded as 
adverse events. However, laboratory value changes that require tre atment or adjustment in 
current therapy are considered adverse events. Where applicable, clinical sequelae (not the 
laboratory abnormality) are to be recorded as the adverse event. Subjects who develop any 
laboratory abnormalities outside the reference ran ge that are deemed clinically meaningful 
during the study period will have follow -up laboratory assessments once a week, or more 
frequently if deemed necessary, until the abnormalities have resolved or returned to within the 
reference range or to the subje ct’s baseline values.  
Subjects will be asked to provide urine samples for drugs of abuse screen and cotinine test, and 
will undergo an alcohol urine or breath test at the times indicated in the Schedule of Assessments 
in Appendix  8. For all female subjects, a pregnancy test and FSH screen for postmenopausal 
women will be performed at the times indicated in the Schedule of Assessments in Appendix  8. 
An Investigator (or designee) will perform a clinical assessment of all clinical laboratory data.  
7.2.3.  Vital Signs  
Supine blood pressure, supine HR, respiratory rat e, and oral body temperature will be assessed at 
the times indicated in the Schedule of Assessments in Appendix  8. Vital signs may also be 
Protocol  CONFIDENTIAL  
Labcorp Drug Development Study: 8493285  AMG 510 20220024  
18 May 2022  Page 35 of 69 
Internal Use Only Medical and Scientific Affairs  performed at other times if judged to be clinically appropriate or if the ongoing review of the 
data suggests a more detailed assessment of vital signs is required.  
All measurements will be performed singly and repeated once if outside the relevant clinical 
reference r ange.  
Subjects must be  supine for at least 5  minutes before blood pressure and heart rate 
measurements. When vital signs are scheduled at the same time as blood draws, the blood draws 
will be obtained at the scheduled timepoint, and the vitals will be obta ined as close to the 
scheduled blood draw as possible, but prior to the blood draw.  
7.2.4.  12-Lead Electrocardiogram  
Resting 12 -lead ECGs will be recorded after the subject has been supine and at rest for at least 
5 minutes at the times indicated in the Schedule of Assessments in Appendix  8. Single 12 -lead 
ECGs will be repeated twice, and an average taken of the 3 readings, if either of the following 
criteria app ly: 
 QTcF is 500 ms 
 QTcF change from the baseline (predose) is 60 ms. 
Additional 12 -lead ECGs may be performed at other times if judged to be clinically appropriate 
or if the ongoing review of the data suggests a more detailed assessment of ECGs is required. 
The Investigator (or designee) will perform a clinical assessment of each 12 -lead ECG.  
7.2.5.  Physical Examination  
A full physical examination or symptom -directed physical examination will be performed at the 
timepoints specified in the Schedule of Asse ssments in Appendix  8. 
8. SAMPLE SIZE AND DATA ANALYSIS  
8.1. Determination of Sample Size  
Approximately 14 subjects will be enrolled in order that approximately  12 subjects complete the 
study. The sample size for this study was based upon precedent set by other PK studies of a 
similar nature and was not based on power calculations.  
8.2. Analysis Populations  
8.2.1.  Pharmacokinetic Population  
The PK population will include all  subjects who received at least 1 dose of sotorasib and have 
evaluable PK data. The PK population for the primary endpoint analysis will include all subjects 
who received both sotorasib , and sotorasib in combination with omeprazole and an acidic 
Protocol  CONFIDENTIAL  
Labcorp Drug Development Study: 8493285  AMG 510 20220024  
18 May 2022  Page 36 of 69 
Internal Use Only Medical and Scientific Affairs  beverage, and have evaluable PK data. A subject will be excluded from the PK summary 
statistics and statistical analysis if the subject has an adverse event of vomiting that occurs at or 
before 2 times median t max or diarrhea within 24 hours of dosing.  
8.2.2.  Safety Popula tion 
The safety population will include all subjects who received at least 1 dose of sotorasib and have 
at least 1 postdose safety assessment.  
8.3. Pharmacokinetic Analyses  
The plasma PK parameters of sotorasib on Days 1 and 9 will be calculated using standard 
noncompartmental methods.  
The primary PK parameters are C max, AUC inf, and AUC last for sotorasib. A linear mixed -effects 
model will be used to analyze log -transformed primary PK parameters. The model will assume 
fixed effect for treatment and a random effec t for subject. Geometric mean ratios for C max and 
AUC values and associated 90  confidence intervals (Test/Reference) will be estimated. The 
“Reference” treatment for PK analysis will be sotorasib administered alone with water, while the 
“Test” treatment w ill be omeprazole administered in combination with sotorasib and an acidic 
beverage.  
Additional parameters may be calculated. Specific details will be presented in the Statistical 
Analysis Plan for this study.  
8.4. Safety Analysis  
The number and percentage of subjects reporting any adverse events will be tabulated by 
Medical Dictionary for Regulatory Activities system organ class and preferred term. Tables of 
fatal adverse events, serious adverse events, adverse events leading to withdrawal from 
investigational  product or other protocol -required therapies, and significant treatment -emergent 
adverse events will also be provided. Subject -level data may be provided instead of tables if the 
subject incidence is low.  
Endpoints for clinical laboratory tests, ECG, and vital signs will be summarized.  
8.5. Interim Analysis  
No interim analyses are planned for this study.  
9. REFERENCES  
1. Amgen. AMG 510 – Investigator’s Brochure. (Version 6.2). 25 February 2022.  
2. Hobbs GA, Der CJ, Rossman KL. RAS isoforms and mutations in cancer at a g lance. J Cell 
Sci. 2016;129(7):1287 -1292.  
Protocol  CONFIDENTIAL  
Labcorp Drug Development Study: 8493285  AMG 510 20220024  
18 May 2022  Page 37 of 69 
Internal Use Only Medical and Scientific Affairs  3. Ostrem JM, Shokat KM. Direct small -molecule inhibitors of KRAS; from structural insights 
to mechanism -based design. Nat Rev Drug Discov . 2016;15(11):771 -785. 
4. Patricelli MP, Janes MR, Li LS, et al. Selective inhibit ion of oncogenic KRAS output with 
small molecules targeting the inactive state. Cancer Discov . 2016;6:316 -329. 
5. Canon J, Rex K, Saiki AY, et al. The clinical KRAS (G12C) inhibitor AMG 510 drives anti -
tumour immunity. Nature . 2019;575:217 -223. 
6. The AACR Project GENIE Consortium. AACR Project GENIE: Powering Precision 
Medicine Through an International Consortium. Cancer Discov . 2017;7(8):818 -831. 
7. Biernacka A, Tsongalis PD, Peterson JD, et al. The potential utility of re -mining results of 
somatic m utation testing: KRAS status in lung adenocarcinoma. Cancer Genet . 
2016;209(5):195 -198. 
8. Neumann J, Zeindl -Eberhart E, Kirchner T, Jung A. Frequency and type of KRAS mutations 
in routine diagnostic analysis of metastatic colorectal cancer. Pathol Res Pract . 
2009;205(12):858 -862. 
9. Janes MR, Zhang J, Li LS, et al. Targeting KRAS mutant cancers with a covalent G12C -
specific inhibitor. Cell. 2018;172(3):578 -589. 
10. McDonald ER, de Weck A, Schlabach MR, et al. Project DRIVE: A compendium of cancer 
dependencies and sy nthetic lethal relationships uncovered by large -scale deep RNAi 
screening. Cell. 2017;170(3):577 -592. 
11. Xie C, Li Y, Li LL, et al. Identification of a new potent inhibitor targeting KRAS in non -
small cell lung cancer cells. Front Pharmacol . 2017;8:823.  
12. Prilo sec (omeprazole) Prescribing Information. Wilmington, DE: AstraZeneca 
Pharmaceuticals LP. September 2012.  
13. Van Leeuwen RW, Peric R, Hussaarts KG, et al. Influence of the acidic beverage cola on the 
absorption of erlotinib in patients with non -small cell lun g cancer. J Clin Oncol . 2016 
Apr 20;34:1309 -1314.  
14. van Seyen M, Colbers A, Abbink EJ, et al. Concomitant Intake of Coca -Cola to Manage the 
Drug -Drug Interaction Between Velpatasvir and Omeprazole Studied in Healthy Volunteers. 
Clin Pharmacol Ther . 2019;106( 5):1093 -1098. doi:10.1002/cpt.1569.  
15. Lange D, Pavao JH, Wu J, Klausner M. Effect of a cola beverage on the bioavailability of 
itraconazole in the presence of H2 blockers. J Clin Pharmacol . 1997 Jun;37(6):535 -540. doi: 
10.1002/j.1552 -4604.1997.tb04332.x. PMI D: 9208361.  
Protocol  CONFIDENTIAL  
Labcorp Drug Development Study: 8493285  AMG 510 20220024  
18 May 2022  Page 38 of 69 
Internal Use Only Medical and Scientific Affairs  16. Chin TW, Loeb M, Fong IW. Effects of an acidic beverage (Coca -Cola) on absorption of 
ketoconazole. Antimicrob Agents Chemother . 1995 Aug;39(8):1671 -1675. doi: 
10.1128/AAC.39.8.1671. PMID: 7486898; PMCID: PMC162805.  
17. Food and Drug Administration LUMAKRASTM (sotorasib) tablets prescribing information. 
Revised May 2021. Amgen. Available at: 
https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214665s000lbl.pdf.  
18. Delgado, C. et al. A unifying approach for GFR estimation: recommendations of the NKF -
ASN Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Disease. J. Am. 
Soc. Nephrol.  2021 Dec; 32(12) :2994 -3015 . doi: https://doi.org/10.1681/ASN.2021070988 . 
Protocol  CONFIDENTIAL  
Labcorp Drug Development Study: 8493285  AMG 510 20220024  
18 May 2022  Page 39 of 69 
Internal Use Only Medical and Scientific Affairs  10. APPENDICES  
Protocol  CONFIDENTIAL  
Labcorp Drug Development Study: 8493285  AMG 510 20220024  
18 May 2022  Page 40 of 69 
Internal  Use Only Medical and Scientific Affairs  Appendix  1: Safety Events: Definitions and Procedures for Recording, Evaluating, 
Follow -up, and Reporting of Adverse Events and Serious Adverse Events  
Definition of Adverse Event  
Adverse Event Definition  
 An adverse event is any untoward medical occurrence in a clinical study subject 
irrespective of a causal relationship with the study treatment.  
 Note: An adverse event can therefore be any unfavorable and unintended sign 
(including an abnormal laboratory finding), symptom, or disease (new or 
exacerbated) temporally associated with the use of a treatment, combination 
product, medical device, or proc edure.  
 Note: Treatment -emergent adverse events will be defined in the Statistical Analysis 
Plan.  
Events Meeting the Adverse Event Definition  
 Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) 
or other safety assessments (eg, electrocardiogram, radiological scans, vital signs 
measurements), including those that worsen from baseline, that are considered 
clinically significant in the medical and scientific judgment of the Investigator (ie, 
not related to progression of under lying disease).  
 Exacerbation of a chronic or intermittent pre -existing condition including either an 
increase in frequency and/or intensity of the condition.  
 New conditions detected or diagnosed after study treatment administration even 
though it may have been present before the start of the study.  
 Signs, symptoms, or the clinical sequelae of a suspected drug -drug interaction.  
 Signs, symptoms, or the clinical sequelae of a suspected overdose of either study 
treatment or a concomitant medication. Overdose per se will not be reported as an 
adverse event/serious adverse event unless it is an intentional overdose taken with 
possible suicidal/self -harming intent. Such overdoses are to be reported regardless 
of sequelae.  
 “Lack of efficacy” or “failure of expecte d pharmacological action” per se will not 
be reported as an adverse event or serious adverse event. Such instances will be 
captured in the efficacy assessments. However, the signs, symptoms, and/or clinical 
sequelae resulting from lack of efficacy will be reported as adverse events or 
serious adverse events if they fulfill the definition of an adverse event or serious 
adverse event.  
Protocol  CONFIDENTIAL  
Labcorp Drug Development Study: 8493285  AMG 510 20220024  
18 May 2022  Page 41 of 69 
Internal  Use Only Medical and Scientific Affairs  Events NOT Meeting the Adverse Event Definition  
 Medical or surgical procedure (eg, endoscopy, appendectomy): the condition that 
leads to the procedure is the AE.  
 Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospital).  
 Anticipated day -to-day fluctuations of pre -existing disease(s) or condition(s) 
present or detected at the start of the study that do not worsen.  
Definition of Serious Adverse Event  
A Serious Adverse Event is defined as any untoward medical occurrence that 
meets at least 1 of the following serious criteria:  
Results in death (fatal)  
Immediately life-threatening  
The term “life -threatening” in the definition of “serious” refers to an event in which 
the subject was at risk of death at the time of the event. It does not refer to an event, 
which hypothetically might have caused death, if it were more severe.  For instance, 
drug-induced hepatitis that resolved without evidence of hepatic failure would not 
be considered life threatening even though drug -induced hepatitis can be fatal.  
Requires in -patient hospitalization or prolongation of existing hospit alization  
In general, hospitalization signifies that the subject has been detained (usually 
involving at least an overnight stay) at the hospital or emergency ward for 
observation and/or treatment that would not have been appropriate in the 
physician’s off ice or outpatient setting. Complications that occur during 
hospitalization are an adverse event. If a complication prolongs hospitalization or 
fulfills any other serious criteria, the event is serious. When in doubt as to whether 
“hospitalization” occurred  or was necessary, the adverse event is to be considered 
serious. Hospitalization for elective treatment of a pre -existing condition that did 
not worsen from baseline is not considered an adverse event.  
Results in persistent or significant disability/inca pacity  
The term “disability” means a substantial disruption of a person’s ability to conduct 
normal life functions. This definition is not intended to include experiences of 
relatively minor medical significance such as uncomplicated headache, nausea, 
vomi ting, diarrhea, influenza, and accidental trauma (eg, sprained ankle) which 
may interfere with or prevent everyday life functions but do not constitute a 
substantial disruption.  
Protocol  CONFIDENTIAL  
Labcorp Drug Development Study: 8493285  AMG 510 20220024  
18 May 2022  Page 42 of 69 
Internal  Use Only Medical and Scientific Affairs  Is a congenital anomaly/birth defect  
Other medically important serious event  
Medical or scientific judgment is to be exercised in deciding whether serious 
adverse event reporting is appropriate in other situations such as important medical 
events that may not be immediately life -threatening or result in death or 
hospitalization bu t may jeopardize the subject or may require medical or surgical 
intervention to prevent 1 of the other outcomes listed in the above definition. These 
events are typically to be considered serious.  
Examples of such events include invasive or malignant cancers, intensive treatment 
in an emergency room or at home for allergic bronchospasm, blood dyscrasias or 
convulsions that do not result in hospitalization, or development of drug 
dependency or drug abuse.  
Recording Adverse Events and Serious Adverse Events  
Adverse Event and Serious Adverse Event Recording  
 When an adverse event or serious adverse event occurs, it is the responsibility of 
the Investigator to review all documentation (eg, hospital progress notes, 
laboratory, and diagnostics reports) rel ated to the event.  
 The Investigator will then record all relevant adverse event/serious adverse event 
information in the Event electronic Case Report Form (eCRF).  
 The Investigator must assign the following adverse event attributes:  
o Adverse event diagnosis or syndrome(s), if known (if not known, signs or 
symptoms);  
o Dates of onset and resolution (if resolved);  
o Did the event start prior to first dose of investigational product;  
o Assessment of seriousness;  
o Severity (or toxicity defined below);  
o Assessment of rela tedness to the investigational product(s) and/or study -
mandated procedures;  
o Action taken; and  
o Outcome of event.  
 If the severity of an adverse event changes from the date of onset to the date of 
resolution, record as a single event with the worst severity  on the appropriate eCRF.   
Protocol  CONFIDENTIAL  
Labcorp Drug Development Study: 8493285  AMG 510 20220024  
18 May 2022  Page 43 of 69 
Internal  Use Only Medical and Scientific Affairs   It is not acceptable for the Investigator to send photocopies of the subject’s medical 
records to the Sponsor in lieu of completion of the appropriate eCRF page.  
 If specifically requested, the Investigator may need to provide additional follow -up 
information, such as discharge summaries, medical records, or extracts from the 
medical records. In this case, all subject identifiers, with the exception of the 
subject number, will be blinded on the copies of the medical records befo re 
submission to the Sponsor.  
 The Investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. In such cases, the diagnosis (not the 
individual signs/symptoms) will be documented as the advers e event/serious 
adverse event.  
Evaluating Adverse Events and Serious Adverse Events  
Assessment of Severity  
The Investigator will make an assessment of severity for each adverse event and 
serious adverse event reported during the study. The assessment of severity will be 
based on the Common Terminology Criteria for Adverse Events (CTCAE) grading 
scale. For the C TCAE grading scale version 5.0, refer to: 
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm . 
Assessment of Causality  
 The Investigator is obligated to assess the relationship between investigational 
product(s), protocol -required therapy, and/or study -mandated procedure and each 
occurrence of each adverse event/serious  adverse event.  
 Relatedness means that there are facts or reasons to support a relationship between 
investigational product and the event.  
 The Investigator will use clinical judgment to determine the relationship.  
 Alternative causes, such as underlying dis ease(s), concomitant therapy, and other 
risk factors, as well as the temporal relationship of the event to study treatment 
administration will be considered and investigated.  
 The Investigator will also consult the Investigator’s Brochure and/or Product 
Information, for marketed products, in his/her assessment.  
 For each adverse event/serious adverse event, the Investigator must document in the 
medical notes that he/she has reviewed the adverse event/serious adverse event and 
has provided an assessment of cau sality.  
 There may be situations in which a serious adverse event has occurred and the 
Investigator has minimal information to include in the initial report. However, it is 
Protocol  CONFIDENTIAL  
Labcorp Drug Development Study: 8493285  AMG 510 20220024  
18 May 2022  Page 44 of 69 
Internal  Use Only Medical and Scientific Affairs  very important that the Investigator always make an assessment of causality for 
every event before the initial transmission of the serious adverse event data.  
 The Investigator may change his/her opinion of causality in light of follow -up 
information and send a serious adverse event follow -up report with the updated 
causality assessment.  
 The causality assessment is 1 of the criteria used when determining regulatory 
reporting requirements.  
Follow -up of Adverse Event and Serious Adverse Event  
 The Investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically indicated or as requested by the 
Sponsor to elucidate the nature and/or causality of the adverse event or serious 
adverse event as fully as possible. This may include additional laboratory tests or 
investigations, histopatho logical examinations, or consultation with other health 
care professionals.  
 If a subject is permanently withdrawn from protocol -required therapies because of a 
serious adverse event, this information must be submitted to the Sponsor.  
 If a subject dies duri ng participation in the study or during a recognized follow -up 
period, the Investigator will provide the Sponsor with a copy of any postmortem 
findings including histopathology.  
 New or updated information will be recorded in the originally completed eCRF.  
 The Investigator will submit any updated serious adverse event data to the Sponsor 
within 24 hours of receipt of the information.  
Reporting of Serious Adverse Event  
Serious Adverse Event Reporting via Paper Serious Adverse Event Report Form  
 Facsimile transmission of the Serious Adverse Event Report Form (see  Figure 2 ) is 
the preferred method to transmit this information.  
 In rare circumstances and in the absence of facsimile equipment, notification by 
telephone is acceptable with a copy of the Serious Adverse Event Report Form sent 
by overnight mail or courier service.  
 Initial notification via telephone does not replace the need for the Investigator to  
complete and sign the Serious Adverse Event Report Form within the designated 
reporting time frames.  
 Once the study has ended, serious event(s) suspected to be related to investigational 
product will be reported to Amgen if the Investigator becomes aware of a serious 
Protocol  CONFIDENTIAL  
Labcorp Drug Development Study: 8493285  AMG 510 20220024  
18 May 2022  Page 45 of 69 
Internal  Use Only Medical and Scientific Affairs  adverse event. The Investigator should use the paper -based Serious Adverse Event 
Report Form to report the event.  
 
Protocol  CONFIDENTIAL  
Labcorp Drug Development Study: 8493285  AMG 510 20220024  
18 May 2022  Page 46 of 69 
Internal  Use Only Medical and Scientific Affairs  Figure  2:  Sample Serious Adverse Event Report Form  
Protocol  CONFIDENTIAL  
Labcorp Drug Development Study: 8493285  AMG 510 20220024  
18 May 2022  Page 47 of 69 
Internal  Use Only Medical and Scientific Affairs   

Protocol  CONFIDENTIAL  
Labcorp Drug Development Study: 8493285  AMG 510 20220024  
18 May 2022  Page 48 of 69 
Internal  Use Only Medical and Scientific Affairs   

Protocol  CONFIDENTIAL  
Labcorp Drug Development Study: 8493285  AMG 510 20220024  
18 May 2022  Page 49 of 69 
Internal  Use Only Medical and Scientific Affairs   

Protocol  CONFIDENTIAL  
Labcorp Drug Development Study: 8493285  AMG 510 20220024  
18 May 2022  Page 50 of 69 
Internal  Use Only Medical and Scientific Affairs  Appendix  2: Clinical Laboratory Evaluations  
Clinical chemistry:  Hematology:  Urinalysis:  
Alanine aminotransferase  
Albumin  
Alkaline phosphatase  
Aspartate aminotransferase  
Blood urea nitrogen  
Calcium  
Chloride  
Cholesterol  
Creatinine  
Direct bilirubina  
Gamma -glutamyl transferase  
Glucose  
Indirect bilirubina 
Inorganic phosphate  
Magnesium  
Potassium  
Sodium  
Total bilirubina 
Total CO2 (measured as 
bicarbonate)  
Total creatine kinase  
Total protein  
Uric acid  Hematocrit  
Hemoglobin  
Mean cell hemoglobin  
Mean cell hemoglobin 
conce ntration  
Mean cell volume  
Platelet count  
Red blood cell (RBC) count  
RBC distribution width  
White blood cell (WBC) count  
WBC differential : 
   Basophils  
   Eosinophils  
   Lymphocytes  
   Monocytes  
   Neutrophils  
 Bilirubin  
Blood  
Color and appearance  
Glucose  
Ketones  
Leukocyte esterase  
Nitrite  
pH 
Protein  
Specific gravity  
Urobilinogen  
Microscopic examination (if 
protein, leukocyte esterase, 
nitrite, or blood is positive)  
Serologyb: Drug screenc: Hormone panel - females 
only:  
Anti-hepatitis B surface antibody  
Anti-hepatitis B core antibody  
Hepatitis B surface antigen  
Hepatitis C antibody  
Human immunodeficiency virus 
(HIV -1 and HIV -2) antibodies 
and p24 antigen  Including but not limited to:  
Amphetamines/methamphetamin
es 
Barbiturates  
Benzodiazepines  
Cocaine (metabolite)  
Cotinine test  
Methadone  
Phencyclidine  
Opiates  
Tetrahydrocannabinol/  
cannabinoids  
Tricyclic antidepressants  
Alcohol urine or alcohol breath 
test (Check -in only)  
 Follicle -stimulating hormoneb 
(postmenopausal females only)  
Serum pregnancy test (human 
chorionic gonadotropin)d 
Urine pregnancy testd 
Other tests : 
International normalized ratio 
(INR)e 
Estimated glomerular filtration 
rate (eGFR)c,f 
Thyroid -stimulating hormoneg 
a Direct and indirect bilirubin will be analyzed if total bilirubin is elevated.  
b Only analyzed at Screening.  
c Only analyzed at Screening and Check -in. 
d Performed at Screening, Check -in, and at the end of study or if a subject is withdrawn early from the  study.  
Performed in serum at Screening and in urine at all other times for all females. A positive urine pregnancy test will be 
confirmed with a serum pregnancy test.  
Protocol  CONFIDENTIAL  
Labcorp Drug Development Study: 8493285  AMG 510 20220024  
18 May 2022  Page 51 of 69 
Internal  Use Only Medical and Scientific Affairs  e International normalized ratio will be tested if hepatotoxicity is suspected, per guid elines presented in Appendix  7. 
f Calculated by the Modification of Diet in Renal Disease equation.  
g. Only analyzed at Screening, Check -in, and at end of study.  
Protocol  CONFIDENTIAL  
Labcorp Drug Development Study: 8493285  AMG 510 20220024  
18 May 2022  Page 52 of 69 
Internal  Use Only Medical and Scientific Affairs  Appendix  3: Total Blood Volume  
The following blood volumes will be withdrawn for each subject.  
 Volume per blood 
sample (mL)  Maximum number 
of blood samples  Total amount of 
blood (mL)  
Clinical laboratory 
evaluations  12.5 4 50.0 
Serology  7.0 1 7.0 
Sotorasib 
pharmacokinetics  4.0 28 112.0  
Total:  169.0  
If extra blood samples are required, the maximum blood volume to be withdrawn per subject will 
not exceed 500  mL. 
Protocol  CONFIDENTIAL  
Labcorp Drug Development Study: 8493285  AMG 510 20220024  
18 May 2022  Page 53 of 69 
Internal  Use Only Medical and Scientific Affairs  Appendix  4: Contraception Requirements  
All subjects must receive pregnancy prevention counseling and be advised of the risk to the fetus 
if they conceive a child during treatment and for 7 days after the end of study (EOS) visit.  
Additional medications given during the study may alter the contraceptive requirements. The  
Investigator must discuss these contraceptive changes with the subject.  
Definitions  
Women of Childbearing Potential:  premenopausal females who are anatomically and 
physiologically capable of becoming pregnant following menarche.  
Women of Nonchildbearing  Potential:  
1. Surgically sterile:  Females who are permanently sterile via hysterectomy, bilateral 
salpingectomy, and/or bilateral oophorectomy by reported medical history and/or medical 
records. Surgical sterilization to have occurred a minimum of 6 weeks, o r at the 
Investigator’s discretion, prior to Screening.  
2. Postmenopausal:  Females at least 45 years of age with amenorrhea for 12 months 
without an alternative medical reason with confirmatory follicle -stimulating hormone 
levels of  40 mIU/mL. The amenorrh ea should not be induced by a medical condition 
such as anorexia nervosa, hypothyroid disease, or polycystic ovarian disease, or by 
extreme exercise. It should not be due to concomitant medications that may have induced 
the amenorrhea such as oral contrace ptives, hormones, gonadotropin -releasing hormones, 
anti-estrogens, or selective estrogen receptor modulators.  
Fertile male:  a male that is considered fertile after puberty.  
Infertile male:  permanently sterile male via bilateral orchiectomy.  
Contraceptio n Requirements  
Female Subjects:  
Only female subjects who are of nonchildbearing potential will be enrolled in the study and are 
not required to use contraception.  
Male Subjects:  
Male subjects with nonchildbearing female partners (as defined above) are not  required to use 
contraception.  
Male subjects (even with a history of vasectomy) with partners of childbearing potential must 
use a male barrier method of contraception (ie, male condom with spermicide) in addition to a 
Protocol  CONFIDENTIAL  
Labcorp Drug Development Study: 8493285  AMG 510 20220024  
18 May 2022  Page 54 of 69 
Internal  Use Only Medical and Scientific Affairs  second method of acceptable contrace ption by female partner from Check -in until 7 days after 
the EOS visit. Acceptable methods of contraception for female partners include:  
 hormonal injection  
 combined oral contraceptive pill or progestin/progestogen -only pill  
 combined hormonal patch  
 combi ned hormonal vaginal ring  
 surgical method (bilateral tubal ligation or regulatory approved method of hysteroscopic 
bilateral tubal occlusion)  
 hormonal implant  
 hormonal or non -hormonal intrauterine device  
 over-the-counter sponge with spermicide  
 cervica l cap with spermicide  
 diaphragm with spermicide.  
Male subjects are required to refrain from donation of sperm from Check -in until 7 days after the 
EOS visit.  
Sexual Abstinence  
Subjects who practice true abstinence, because of the subject’s lifestyle choice (ie, the subject 
should not become abstinent just for the purpose of study participation), are exempt from 
contraceptive requirements. Periodic abstinence (eg, calendar, ovulation, symptothermal, 
postovulation methods) and withdrawal are not accepta ble methods of contraception.  
For subjects who practice true abstinence, subjects must be abstinent for at least 6 months prior 
to Screening and must agree to remain abstinent from the time of signing the Informed Consent 
Form (ICF) until 7  days after the EOS visit.  
Same -sex Relationships  
For subjects who are exclusively in same -sex relationships, contraceptive requirements do not 
apply.  
If a subject who is in a same -sex relationship at the time of signing the ICF becomes engaged in 
a heterosexual relation ship, they must agree to use contraception from the time of signing the 
ICF until 7 days after the EOS visit.   
Protocol  CONFIDENTIAL  
Labcorp Drug Development Study: 8493285  AMG 510 20220024  
18 May 2022  Page 55 of 69 
Internal  Use Only Medical and Scientific Affairs  Appendix  5: Collection of Pregnancy and Lactation Information  
Collection of Pregnancy Information  
Male Subjects with Partners Who Become Pregnant  or Were Pregnant at the Time of Enrollment  
 In the event a male subject fathers a child during treatment, and for an additional 7 days 
after end of study ( EOS), the information will be recorded on the Pregnancy Notification 
Form . The form  (see Figure  3) must be submitted to Amgen Global Patient Safety within 
24 hours of the site’s awareness of the pregnancy. (Note: Sites are not required to provide 
any information on the Pregnancy Notificatio n Form that violates the country or regions 
local privacy laws).  
 The Investigator will attempt to obtain a signed consent for release of pregnancy and 
infant health information directly from the pregnant female partner to obtain additional 
pregnancy inform ation.  
 After obtaining the female partner’s signed consent for release of pregnancy and infant 
health information, the Investigator will collect pregnancy outcome and infant health 
information on the pregnant partner and her baby and complete the pregnancy  
questionnaires. This information will be forwarded to Amgen Global Patient Safety.  
 Generally, infant follow -up will be conducted up to 12 months after the birth of the child 
(if applicable).  
 Any termination of the pregnancy will be reported to Amgen Glob al Patient Safety 
regardless of fetal status (presence or absence of anomalies) or indication for procedure . 
Collection of Lactation Information  
 The Investigator will collect lactation information on any female subject who breastfeeds 
while taking protocol -required therapies through 7 days after EOS.  
 Information will be recorded on the Lactation Notification  Form (Figure  4) and submitted 
to Amgen Global Patient Safety within 24 hours of the Investigator’s awareness of the 
event.  
 Study treatment will be discontinued if the female subject breastfeeds during the study.  
With the female subject’s signed consent for release of mother and infant health information, the 
Investigator will collect mother and infant health information and complete the lactation 
questionnaire on any female subject who breastfeeds while taking protocol -required therapies 
through 7 days after  discontinuing protocol -required therapies.
Protocol  CONFIDENTIAL  
Labcorp Drug Development Study: 8493285  AMG 510 20220024  
18 May 2022  Page 56 of 69 
Internal Use Only Medical and Scientific Affairs  Figure  3:  Pregnancy Notification Form  
 

Protocol  CONFIDENTIAL  
Labcorp Drug Development Study: 8493285  AMG 510 20220024  
18 May 2022  Page 57 of 69 
Internal Use Only Medical and Scientific Affairs  Figure  4:  Lactation Notification Form  
 

Protocol  CONFIDENTIAL  
Labcorp Drug Development Study: 8493285  AMG 510 20220024  
18 May 2022  Page 58 of 69 
Internal Use Only Medical and Scientific Affairs  Appendix  6: Regulatory, Ethical, and Study Oversight Considerations  
Regulatory and Ethical Considerations  
This study will be conducted in accordance with the protocol and with the following:  
 Consensus ethical principles derived from international guidelines including the 
Declaration of Helsinki and Council f or International Organizations of Medical Sciences 
(CIOMS) International Ethical Guidelines.  
 Applicable International Conference on Harmonisation (ICH) Good Clinical Practice 
(GCP) Guidelines.  
 Applicable laws and regulations.  
The protocol, protocol amendme nts, Informed Consent Form (ICF), Investigator’ Brochure, and 
other relevant documents (eg, advertisements) must be submitted to an Institutional Review 
Board (IRB) by the Investigator and reviewed and approved by the IRB before the study is 
initiated.  
Any amendments to the protocol will require IRB and regulatory authority (as locally required) 
approval before implementation of changes made to the study design, except for changes 
necessary to eliminate an immediate hazard to study subjects.  
The Investigato r will be responsible for the following:  
 Providing written summaries of the status of the study to the IRB annually or more 
frequently in accordance with the requirements, policies, and procedures established by 
the IRB.  
 Notifying the IRB of serious advers e events or other significant safety findings as 
required by IRB procedures.  
 Providing oversight of the conduct of the study at the site and adherence to requirements 
of 21 Code of Federal Regulations (CFR), ICH guidelines, the IRB, European regulation 
536/2014 for clinical studies (if applicable), and all other applicable local regulations.  
Finances and Insurance  
Financing and insurance will be addressed in a separate agreement.  
Informed Consent  
An initial sample ICF will be provided for the Investigato r (or designee) to prepare the informed 
consent document to be used at his or her site. Updates to the sample ICF are to be 
communicated formally in writing from the Study Manager to the Investigator. The written ICF 
is to be prepared in the language(s) of  the potential study participant population.  
Protocol  CONFIDENTIAL  
Labcorp Drug Development Study: 8493285  AMG 510 20220024  
18 May 2022  Page 59 of 69 
Internal Use Only Medical and Scientific Affairs  The Investigator or his/her delegated representative will explain to the subject, or his/her legally 
authorized representative, the aims, methods, anticipated benefits, and potential hazards of the 
study before any protocol -specific screening procedures or any investigational product(s) is/are 
administered and answer all questions regarding the study.  
Subjects must be informed that their participation is voluntary. Subjects or their legally 
authorized representat ive (defined as an individual or other body authorized under applicable law 
to consent, on behalf of a prospective subject, to the subject’s participation in the clinical study) 
will then be required to sign a statement of informed consent that meets the r equirements of 
21 CFR 50, local regulations, ICH guidelines, and the IRB or study site.  
The medical record must include a statement that written informed consent was obtained before 
the subject was enrolled in the study and the date the written consent was  obtained. The 
authorized person obtaining the informed consent must also sign the ICF.  
The acquisition of informed consent and the subject’s agreement or refusal of his/her notification 
of the primary care physician is to be documented in the subject’s me dical records, and the ICF 
is to be signed and personally dated by the subject or a legally acceptable representative and by 
the person who conducted the informed consent discussion. Subject withdrawal of consent or 
discontinuation from study treatment and /or procedures must also be documented in the subject’s 
medical records.  
Subjects must be re -consented to the most current version of the ICF during their participation in 
the study.  
The original signed ICF is to be retained in accordance with institutiona l policy, and a copy of 
the ICF must be provided to the subject or the subject’s legally authorized representative.  
If a potential subject is illiterate or visually impaired and does not have a legally acceptable 
representative, the Investigator must provi de an impartial witness to read the ICF to the subject 
and must allow for questions. Thereafter, both the subject and the witness must sign the ICF to 
attest that informed consent was freely given and understood. (Refer to ICH GCP guideline, 
Section  4.8.9. ) 
A subject who is rescreened is not required to sign another ICF if the rescreening occurs within 
21 days from the previous ICF signature date and the same version of the ICF is in use at the 
time of rescreening.  
Subject Data Prote ction 
The Investigator must ensure that the subject’s confidentiality is maintained for documents 
submitted to the Sponsor.  
Subjects will be assigned a unique identifier by the Sponsor (or designee). Any subject records or 
datasets that are transferred to the Sponsor will contai n the identifier only; subject names or any 
information which would make the subject identifiable will not be transferred.  
Protocol  CONFIDENTIAL  
Labcorp Drug Development Study: 8493285  AMG 510 20220024  
18 May 2022  Page 60 of 69 
Internal Use Only Medical and Scientific Affairs  On the electronic Case Report Form (eCRF) demographics page, in addition to the unique 
subject identification number ( Section  4.4), include the age at time of enrollment.  
For serious adverse events reported to the Sponsor (or designee), subjects are to be identified by 
their unique subject identification number ( Section  4.4), initials (for faxed reports, in accordance 
with local laws and regulations) and age (in accordance with local laws and regulations).  
Documents that are not submitted to the Sponsor (eg, signed ICFs) are to be kep t in confidence 
by the Investigator, except as described below.  
In compliance with ICH GCP Guidelines , it is required that the Investigator and institution 
permit authorized representatives of the company, of the regulatory agency(s), and the IRB direct 
access to review the subject’s original medical records for verification of study -related 
procedures and data. Direct access includes examining, analyzing, verifying, and reproducing 
any records and reports that are important to the evaluation of the study.  
The Investigator is obligated to inform and obtain the consent of the subject to permit such 
individuals to have access to his/her study -related records, including personal information.  
Disclosure  
All information provided regarding the study, as well as al l information collected and/or 
documented during the course of the study, will be regarded as confidential information of the 
Sponsor, Amgen Inc. The Investigator (or designee) agrees not to disclose such information in 
any way without prior written permis sion from the Sponsor. The information in this document 
cannot be used for any purpose other than the evaluation or conduct of the clinical investigation 
without the prior written permission from the Sponsor.  
The Investigator must ensure that the subject’s  confidentiality is maintained for documents 
submitted to Amgen.  
Subjects will be assigned a unique identifier by the Sponsor (or designee). Any subject records or 
datasets that are transferred to the Sponsor will contain the identifier only; subject names  or any 
information which would make the subject identifiable will not be transferred.  
On the eCRF demographics page, in addition to the unique subject identification number 
(Section  4.4), include the age at time of enrollment.  
For serious adverse events reported to Amgen, subjects are to be identified by their unique 
subject identification number ( Section  4.4), initials (for faxed reports, in accordance with local 
laws and regulations), and age (in accordance with local laws and regulations).  
Documents that are not submitt ed to Amgen (eg, signed ICFs) are to be kept in confidence by the 
Investigator, except as described below.  
Protocol  CONFIDENTIAL  
Labcorp Drug Development Study: 8493285  AMG 510 20220024  
18 May 2022  Page 61 of 69 
Internal Use Only Medical and Scientific Affairs  Data Quality Assurance  
The following data quality steps will be implemented:  
 All relevant subject data relating to the study will be recorded on eCRF s unless directly 
transmitted to the Sponsor or designee electronically (eg, laboratory data). The 
Investigator is responsible for verifying that data entries are accurate and correct by 
electronically signing the eCRF.  
 The Investigator must maintain accur ate documentation (source data) that supports the 
information entered in the eCRF.  
 The Investigator must permit study -related monitoring, audits, IRB review, and 
regulatory agency inspections and provide direct access to source data  documents.  
 The Sponsor or designee is responsible  for the data management of this study including 
quality checking of the data. Predefined agreed risks, monitoring thresholds, quality 
tolerance thresholds, controls, and mitigation plans will be documented in a risk 
management re gister. Additional details of quality checking to be performed on the data 
may be included in a Data Management Plan.  
 A Study Monitor will perform ongoing source data verification to confirm that data 
entered into the eCRF by authorized site personnel are accurate, complete, and verifiable 
from source documents; that the safety and rights of subjects are being protected; and that 
the study is being conducted in accordance with the currently approved protocol and any 
other study agreements, ICH GCP, and all applicable regulatory requirements.  
 Records and documents, including signed ICFs, pertaining to the conduct of this study 
must be retained by the Investigator in accordance with 21 CFR 312.62(c) unless  local 
regulations or institutional policies require a longer retention period. No records may be 
destroyed during the retention period without the written approval of the Sponsor. No 
records may be transferred to another location or party without written notification to the 
Sponsor.  
Investigator Documentation  Responsibilities  
All individual, subject -specific study data will also be entered into a 21  CFR Part  11-compliant 
electronic data capture (EDC) system on an eCRF in a timely fashion.  
All data generated from external sources (eg, laboratory and bioanalytic al data), and transmitted 
to the Sponsor or designee electronically, will be integrated with the subject’s eCRF data in 
accordance with the Data Management Plan.  
An eCRF must be completed for each enrolled subject who undergoes any screening procedures, 
according to the eCRF completion instructions. The Sponsor or Contract Research Organization 
will review the supporting source documentation against the data entered into the eCRFs to 
Protocol  CONFIDENTIAL  
Labcorp Drug Development Study: 8493285  AMG 510 20220024  
18 May 2022  Page 62 of 69 
Internal Use Only Medical and Scientific Affairs  verify the accuracy of the electronic data. The Investigator will ensure t hat corrections are made 
to the eCRFs and that data queries are resolved in a timely fashion by the study staff.  
The Investigator will sign and date the eCRF via the EDC system’s electronic signature 
procedure. These signatures will indicate that the Inves tigator reviewed and approved the data on 
the eCRF, data queries, and site notifications.  
Publications  
The policy for publication of data obtained during this study will be documented in the Clinical 
Study Agreement.  
 
Protocol  CONFIDENTIAL  
Labcorp Drug Development Study: 8493285  AMG 510 20220024  
18 May 2022  Page 63 of 69 
Internal Use Only Medical and Scientific Affairs  Appendix  7: Hepatotoxicity Stopping Rules: Suggested Actions and Follow -up Assessments  
Subjects with abnormal hepatic laboratory values (ie, alkaline phosphatase [ALP], aspartate 
aminotransferase [AST], alanine aminotransferase [ALT], total bilirubin [TBL]) and/or 
international normalized ra tio (INR) and/or signs/symptoms of hepatitis (as described below) 
may meet the criteria for withholding or permanent discontinuation of Amgen investigational 
product or other protocol -required therapies, as specified in the Guidance for Industry 
Drug -Induc ed Liver Injury: Premarketing Clinical Evaluation, July 2009.  
Criteria for Withholding and/or Permanent Discontinuation of Amgen Investigational 
Product and Other Protocol -required Therapies Due to Potential Hepatotoxicity  
The following stopping and/or withholding rules apply to subjects for whom another cause of 
their changes in liver biomarkers (TBL, INR, and transaminases) has not been identified.  
Important alternative causes for elevated AST/ALT and/or TBL values include, but are not 
limited to:  
 Hepatobiliary tract disease  
 Viral hepatitis (eg, hepatitis A/B/C/D/E, Epstein -Barr Virus, cytomegalo virus, herpes 
simplex virus, varicella, toxoplasmosis, and parvovirus)  
 Right -sided heart failure, hypotension, or any cause of hypoxia to the liver causing 
ischemia  
 Exposure to hepatotoxic agents/drugs or hepatotoxins, including herbal and dietary 
suppleme nts, plants, and mushrooms  
 Heritable disorders causing impaired glucuronidation (eg, Gilbert’s syndrome, 
Crigler -Najjar syndrome) and drugs that inhibit bilirubin glucuronidation (eg, indinavir, 
atazanavir)  
 Alpha -one antitrypsin deficiency  
 Alcoholic hepati tis 
 Autoimmune hepatitis  
 Wilson’s disease and hemochromatosis  
 Nonalcoholic fatty liver disease including steatohepatitis  
 Non-hepatic causes (eg, rhabdomylosis, hemolysis).  
If investigational product(s) is/are withheld, the subject is to be followed for possible 
drug-induced liver injury (DILI) according to recommendations in the last section of this 
appendix.  
Protocol  CONFIDENTIAL  
Labcorp Drug Development Study: 8493285  AMG 510 20220024  
18 May 2022  Page 64 of 69 
Internal Use Only Medical and Scientific Affairs  Rechallenge may be considered if an alternative cause for impaired liver tests (ALT, AST, ALP) 
and/or elevated TBL is discovered and the laboratory abnormalities resolve to normal or baseline 
(see next section in this appendix).  
Table  2: Conditions for Withholding and/or Permanent Discontinuation of Amgen 
Investigational Product and Other Protocol -required Therapies Due to 
Potential Hepatotoxicity  
Analyte  Temporary Withholding  Permanent Discontinuation  
TBL  3x ULN at any time  2x ULN  
INR -- 
OR 1.5x ULN (for subjects 
not on anticoagulation 
therapy)  
AND  
AST/ALT  8x ULN at any time  
5x ULN but 8x ULN for 2 weeks  
5x ULN but 8x ULN and unable to 
adhere to enhanced monitoring schedule  
3x ULN with clinical signs or symptoms 
that are consistent with hepatitis (such as 
right upper quadrant pain/tenderness, fever, 
nausea, vomiting, and jaundice)  
OR In the presence of no 
important alternative 
causes for elevated 
AST/ALT and/or TBL 
values  
3x ULN (when baseline 
was  ULN)  
ALP  8x ULN at any time  -- 
Abbreviations: ALP  alkaline phosphatase; ALT  alanine aminotransferase; AST  aspartate aminotransferase; 
INR  international normalized ratio; TBL  total bilirubin; ULN  upper limit of normal.  
 
Criteria for Rechallenge of Amgen Investigational Product and O ther Protocol -required 
Therapies After Potential Hepatotoxicity  
The decision to rechallenge the subject is to be discussed and agreed upon unanimously by the 
subject, Investigator, and Amgen.  
If signs or symptoms recur with r echallenge, then sotorasib is to be permanently discontinued.  
Protocol  CONFIDENTIAL  
Labcorp Drug Development Study: 8493285  AMG 510 20220024  
18 May 2022  Page 65 of 69 
Internal Use Only Medical and Scientific Affairs  Subjects who clearly meet the criteria for permanent discontinuation (as described in Table  2) are 
never to be rechallenged.  
Drug -induced Liver Injury Reporting and Additional Assessments  
Reporting  
To facilitate appropriate monitoring for signals of DILI, cases of concurrent AST or ALT and 
TBL and/or INR elevation, according to the criteria specified above, require the following:  
 The event is to be reported to Amgen as a serious adverse event within 24 hours of 
discovery or notification of the event (i.e., before additional etiologic investigations have 
been concluded).  
 The appropriate electronic Case Report Form (eCRF) that captures information necessary 
to facilitate the evaluat ion of treatment -emergent liver abnormalities is to be completed 
and sent to Amgen.  
Other events of hepatotoxicity and potential DILI are to be reported as serious adverse events if 
they meet the criteria for a serious adverse event defined in Appendix  1. 
Additional Clinical Assessments and Observation  
All subjects in whom investigational product(s) or protocol -required therapies is/are withheld 
(either permanently or conditionally) due to potential DILI as specified in Table  2 or who 
exper ience AST or ALT elevations 3 x upper limit of normal (ULN) or 2 -fold increases above 
baseline values for subjects with elevated values before drug are to undergo a period of “close 
observation” until abnormalities return to normal or to the subject’s baseline levels.  
Assessments that are to be performed during this period include:  
 Repeat AST, ALT, ALP, bilirubin (total and direct), and INR within 24 hours  
 In cases of TBL 2x ULN or INR  1.5, retesting of liver tests, bilirubin (total and direct) 
and INR is to be performed every 24 hours until laboratory abnormalities improve.  
Testing frequency of the above laboratory tests may decrease if the abnormalities stabilize or the 
investigational product(s) or protocol -required therapies has/have been discontinued AND the 
subject is asymptomatic.  
Initiate investigation  of alternative causes for elevated AST or ALT and/or elevated TBL.  
The following are to be considered depending on the clinical situation:  
 Complete blood count with differential to assess fo r eosinophilia  
Protocol  CONFIDENTIAL  
Labcorp Drug Development Study: 8493285  AMG 510 20220024  
18 May 2022  Page 66 of 69 
Internal Use Only Medical and Scientific Affairs   Serum total immunoglobulin G, anti -nuclear antibody anti -smooth muscle antibody, and 
liver kidney microsomal antibody -1 to assess for autoimmune hepatitis  
 Serum acetaminophen (paracetamol) levels  
 A more detailed history of:  
o Prior and/or conc urrent disease or illness  
o Exposure to environmental and/or industrial chemical agents  
o Symptoms (if applicable) including right upper quadrant pain, hypersensitivity -
type reactions, fatigue, nausea, vomiting, and fever  
o Prior and/or concurrent use of alcohol , recreational drugs, and special diets  
o Concomitant use of medications (including nonprescription medicines and herbal 
and dietary supplements), plants, and mushrooms  
 Viral serologies  
 Creatine phosphokinase, haptoglobin, lactate dehydrogenase, and peripher al blood smear  
 Appropriate liver imaging if clinically indicated  
 Appropriate blood sampling for pharmacokinetic analysis, if this has not already been 
collected  
 Hepatology consult (liver biopsy may be considered in consultation with a hepatologist).  
Follow the subject and the laboratory tests (ALT, AST, TBL, INR) until all laboratory 
abnormalities return to baseline or normal or are considered stable by the Investigator. The 
“close obser vation period” is to continue for a minimum of 4 weeks after discontinuation of all 
investigational product(s) and protocol -required therapies.  
The potential DILI event and additional information such as medical history, concomitant 
medications, and laboratory results must be captured in the corresponding eCRFs.  
 
Protocol  CONFIDENTIAL  
Labcorp Drug Development Study: 8493285  AMG 510 20220024  
18 May 2022  Page 67 of 69 
Internal Use Only Medical and Scientific Affairs  Appendix  8: Schedule of Assessments
Protocol  CONFIDENTIAL  
Labcorp Drug Development: 8493285  AMG 510 20220024  
18 May 2022  Page 68 of 69 
Internal Use Only Medical and Scientific Affairs   
   Study Procedures  Screening  Check -
in Sotorasib (Day 1) and Omeprazole (Day 4 -8) 
Alone  Sotorasib in Combination with 
Omeprazole and acidic beverage  
Days -28  
to -2 Day -1 Day 1  Day 2  Day 3  Days 4 to 7  Day 8  Day 9  Day 10  Day 11  
(EOS/ET)  
Confined to the CRU    X X X X X X X X X 
Outpatient Visit  X                  
Inclusion/Exclusion Criteria  X X                
Informed Consent  X                  
Demographics  X                  
Serology  X                 
Medical History  X Xa               
Height and BMI  X                 
Weight  X X               Xb 
Drug Screen  X X                
Alcohol Test   X                
Pregnancy Test (females only)c X X               Xb 
FSH (postmenopausal females 
only)  X                 
12-lead Electrocardiogramd X X X       X   Xb 
Vital Signse X X X X  X   X X  Xb 
Clinical Laboratory Evaluationsf X X        X      Xb 
eGFRg X X                
Thyroid -stimulating Hormone  X X        X 
Physical Examinationh  X X               Xb 
Sotorasib Dosei     X       X    
Omeprazole Dosej          X X X     
Sotorasib PK Blood Samplesk     X X X    X X X 
Adverse Event Monitoringl   X 
Serious Adverse Event 
Monitoringl X X 
Prior/Concomitant Medicationsm X X 
Protocol  CONFIDENTIAL  
Labcorp Drug Development: 8493285  AMG 510 20220024  
18 May 2022  Page 69 of 69 
Internal Use Only Medical and Scientific Affairs  Abbreviations: BMI   body mass index; CRU   Clinical Research Unit; eGFR  estimated glomerular filtration rate; EO S  end of study; AT  early termination; 
FSH  follicle -stimulating hormone; PK   pharmacokinetic.  
a Interim medical history only.  
b Assessment to be performed at the EOS or ET.  
c Performed in serum at Screening and in urine at all other times. A positive ur ine pregnancy test will be confirmed with a serum pregnancy test.  
d Electrocardiograms (ECGs) will be collected after the subject has rested in the supine position for at least 5  minutes, and will be obtained prior to the scheduled blood 
draws. ECGs will b e assessed at Screening, Check -in, at predose on Days 1 and 9, and at 0.5, 2, and 4 hours following sotorasib  administration; and at EOS or ET. 
Triplicate ECGs will only be collected at Screening and Check -in if needed to verify eligibility criteria. The 3 0-minute postdose ECG measurement will have a 
collection window of  5 minutes, the 2 -hour postdose ECG measurement will have a collection window of  5 minutes, and the 4 -hour postdose ECG measurement 
will have a collection window of  10 minutes.  
e Vital  signs measurements (oral body temperature, respiratory rate, supine blood pressure, and supine heart rate) will be carried ou t, prior to having blood drawn, at 
Screening, Check -in, predose, and at 1, 24, and 48 hours after each dose of sotorasib, and at E OS or ET. Blood pressure and heart rate will be measured using the same 
arm for each reading after the subject has been resting in the supine position for at least 5  minutes.  
f Clinical chemistry (fasted at least 8  hours), hematology, and urinalysis.  
g eGFR will be calculated using the Modification of Diet in Renal Disease equation.  
h A full physical examination at Screening and  Check -in and a  symptom -directed physical examination at EOS or ET.  
i Dose administration of sotorasib  is to occur during the mornings of Days 1 and 9 following an overnight fast of at least 10  hours. On Day 9, sotorasib administration 
will occur within 5 minutes after administration of omeprazole with  an acidic beverage  (Coca -Cola). 
j Dose administration of omeprazole is to occur during the mornings of Days 4 through 9 following an overnight fast of at least  10 hours.  
k Blood samples for determination of sotorasib  plasma concentrations and  PK parameters  will be collected:  Predose (Hour  0), 0.5 , 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36,  and 
48 hours postdose following administration of sotorasib  on Days 1 and 9. The PK sample collected 30  minutes postdose will have a sampling window of  2 minutes, 
samples collected from 1 through 3  hours postdose will have a sampling window of  5 minutes, samples collected from 4 through 10  hours postdose will have a 
sampling window of  10 minutes, and samples collected from 12 through 48  hours postdose will have a sampling window of  20 minutes. Times of all PK samples 
will be recorded to the nearest minute.  
l Adverse events will be recorded from initiation of study treatment on Day 1 until EOS or ET. Serious adverse events will be r ecorded from the time the subject signs the 
Informed Consent Form throu gh 30 days after the last dose of study treatment or until EOS or ET (whichever is later).  
m Prior and concomitant medication administration will be recorded from the time the subject signs the Informed Consent Form. I n addition, all Investigator -approved 
medications (prescription or over the counter), all herbal medicines (eg, St. John’s wort), vitamins, and supplements taken b y a subject within 30  days or 5  half-lives 
(whichever is longer) prior to enrollment will be recorded on the subject’s electronic C ase Report Form.  
 